Podcasts about Phase

Missouri will decide whether to eventually do away with that state's individual income tax in an effort to better compete in the heartland. The ballot measure, titled Amendment 5, would enable lawmakers to increase and expand Missouri's sales tax with the goal of eventually replacing personal income tax. The amendment doesn't specify which goods or services would face new taxes, though Governor Mike Kehoe is against increasing levies on healthcare, real estate, or agriculture. FOX's Eben Brown speaks with Madison Alworth, FOX Business Network correspondent reporting from Kansas City, MO, who explains the pros and cons of this decision, and what Amendment 5 looks to accomplish. Click Here⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ To Follow 'The FOX News Rundown: Evening Edition' Learn more about your ad choices. Visit podcastchoices.com/adchoices

Am Ende steht die unbequemste Frage: Meisterschaft oder Mittelmaß? Der Epilog bringt Michaels fünf Erkenntnisse auf den Punkt: In Ich-Form, ungeschönt.„Ich vermeide die Wahrheit über meine Führung, weil ich Angst habe vor dem Unterschied zwischen ‚Ich denke, ich führe gut' und ‚So führe ich wirklich.'"Mittelmaß ist keine Phase. Mittelmaß ist eine Entscheidung.Das Märchen ist zu Ende erzählt. Immer Dienstags gibt es eine kurze Videopodcast Folge von mir, wo ich mir ein Führungsmärchen als Impuls anschaue.

-- On the Show: -- Rick Wilson, longtime Republican political strategist and co-founder of the Lincoln Project, joins us on Substack Live to discuss Trump's decline and Democratic midterm strategy -- Donald Trump faces critical weapon shortages while Iranian forces maintain effective control over the strategic Strait of Hormuz -- Donald Trump fills his Truth Social feed with AI graphics before abruptly claiming that he called off an attack against Iran -- Rep. Max Miller releases a video denying domestic abuse claims filed by his ex-wife Emily Moreno, involving a child's broken collarbone -- Capital One reveals that its anti-money-laundering experts shut down more than 300 bank accounts associated with Donald Trump -- Donald Trump claims he personally earned $75 billion for the nation through Intel during a press brief on Air Force One -- Robert F. Kennedy Jr. lashes out at Dana Bash during an interview about vaccines by accusing her of scaring the public -- On the Bonus Show: Three dead in Idaho In-N-Out shooting, Blanche assures skeptical senators the anti-weaponization fund is dead, Trump "wins" his Bedminster club championship, and much more...

Most real estate operators say they're using AI. Very few have built their entire company around it. In this episode, Neal Bawa, CEO of Grocapitus, breaks down the four-phase process his 20-person team used over the past 18 months to become what he calls an AI-first real estate company. From getting every employee certified on custom GPTs in phase one, to building proprietary web-hosted dashboards that pull live data from seven different property management systems in phase four, Neal is specific about what they built, what tools they used, how much it cost, and what it actually changed about how they operate. If you want to know what implementing AI at the company level looks like in practice, this is the episode. About Neal Bawa Neal Bawa is the CEO of Grocapitus and MultifamilyU, where he manages a $436 million AI-powered portfolio across 25 projects in 11 states. Known as the Mad Scientist of Multifamily, Neal has built one of the most data-driven operations in the real estate industry and has made more than 300 podcast appearances sharing that framework with investors. His free investor education platform at MultifamilyU has tens of thousands of subscribers and runs eight webinars per year at no cost. What We Cover in This Episode What it actually means to declare your company AI-first and what changed internally at Grocapitus when they did How Neal tied AI adoption to compensation, bonuses, and continued employment — the carrot and stick system that drove company-wide adoption Phase one: getting every employee certified on ChatGPT and building 300 custom GPTs in four months Phase two: connecting Zoom, Slack, Asana, and Google Drive through native integrations and Zapier to automate meeting workflows Phase three: why they moved to Claude for rent comps, underwriting, and web scraping — and why ChatGPT couldn't do the job How Claude Code differs from Claude Chat and Claude Cowork, and why that distinction matters for automation Phase four: turning every employee into a programmer using GitHub Codespaces — no coding knowledge required How they built a proprietary MySQL dashboard that pulls live data from seven different property management systems simultaneously Why 99% of property managers are not compliant with the industry standard of three phone calls and three text messages to every lead — and how Neal can now see this in real time across his entire portfolio How AI affected headcount — no layoffs, but three to four open requisitions closed and employees working an average of one to one and a half hours less per day Phase five on the horizon: AI handling 100% of incoming calls at their properties Neal's plan to offer this dashboard-building capability to the top 50 property management companies in the US Why Haiku outperforms Sonnet for teams that keep running out of Claude tokens Neal's interest rate prediction through the end of 2026 Key Insight Neal makes a claim that should stop most operators cold: 99% of leads at managed properties do not receive three phone calls and three text messages, the industry standard for lead follow-up. Most don't even get a second call. For years, this was invisible — property managers self-reported compliance, and nobody could verify it. Neal's phase four dashboard changes that. For the first time, he can walk into a Monday morning meeting and show every property manager exactly where they rank against each other, how long they take to respond to a lead, and how many of their leads are being processed correctly. He doesn't have to say a word. The data does it. Why This Episode Matters Neal isn't describing what AI might do for real estate someday. He's describing what his 20-person team built in the last 18 months, with zero consultants hired, on $25 per month Claude accounts. The playbook he lays out — phased adoption, compensation tied to AI competency, tools connected in sequence — is something any operator can start applying at their own scale. If you're still thinking of AI as a tool you use occasionally rather than a system your company runs on, this episode draws a clear line between those two approaches. Find Out More Website: https://www.grocapitus.com Free Investor Club (always free, 8 webinars per year): https://multifamilyu.com/club Location Magic eBook: https://multifamilyu.com/lp/location-magic-ebook/ Physical Book: https://multifamilyu.com/book Sponsors Today's episode is brought to you by Green Property Management, managing everything from single family homes to apartment complexes in the West Michigan area. https://www.livegreenlocal.com And RCB & Associates, helping Michigan-based real estate investors and small business owners navigate the complex world of health insurance and Medicare benefits. https://www.rcbassociatesllc.com

The boys get together to talk through the loan of Nico Dubersarsky and the signing of Jorge Alastuey. Then they recap Saturday's loss against Colorado Rapids before closing out the episode with a preview of the first Leagues Cup "Phase 1" match against Club Tijuana. 0:30 - Intro 5:30 - Austin FC loans Nico Dubersarsky & signs Jorge Alastuey 13:05 - Third kit pre-release party for STHs 14:40 - Lineup reactions 26:40 - Colorado Rapids recap 1:07:20 - Postgame takeaways 1:22:35 - Club Tijuana preview Sign up today for our new Patreon and join in on all the additional fun in The North End! Visit our website for match preview articles, weekly MLS picks and access to our salary cap and roster spreadsheets! Follow the podcast on socials YouTube Instagram Bluesky Threads Twitter Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Welcome to the Mind Muscle Connection Podcast!Fat loss requires a calorie deficit, but there is a point where low energy availability can start creating more stress on the body. In this episode, I break down how to estimate the stress of a fat loss phase using the energy availability equation and what it can tell you about whether you may be under fueling.I also explain the limitations of this equation, why body fat levels and individual differences matter, and the signs to look for when a deficit may be too aggressive. I cover how low energy availability impacts recovery, hormones, training performance, and why spending time outside of a deficit is important for long term progress.If you've wondered whether your fat loss phase is too stressful or when to take a break, this episode will help you know what to look for. Let's talk about:Body Recomp WorkshopWhat Is Energy Availability?How to Calculate Energy AvailabilityEnergy Availability ExamplesUnderstanding Fat Free MassHow Low Energy Availability Impacts the BodyWhen Problems Start to Show UpWhy Women May Be More Sensitive to Low Energy AvailabilityEarly Adaptations to Low Energy AvailabilityLong Term Effects of Staying Too LowWhy You Need Time Outside of a DeficitLimitations of the Energy Availability EquationTracking Exercise and Calorie Estimate ErrorsWhy Body Fat Levels MatterOther Factors That Impact Your ResponseMarkers to Look at During Fat LossUsing Blood Work to Assess Low Energy AvailabilityWhen Low Energy Availability Becomes a ProblemHow to Increase Energy AvailabilityDiet Breaks, Refeeds, and Building PhasesHow Carbohydrates Can Help During Fat LossFinal Takeaways on Energy AvailabilityBody Recomp Workshop Replay: HEREFollow me on Instagram for more information and education: jeffhoehn_How You Can Work With Me?: HERECoaching application: HERE

An innovative biopharmaceutical company dedicated to elevating treatment effectiveness, right where care begins. The Company develops long-acting, controlled-release drugs designed to deliver therapy precisely at the site of care, addressing critical unmet medical needs across a wide and diverse pipeline spanning surgical care, metabolic diseases, and beyond. PolyPid's lead product, D-PLEX₁₀₀, successfully met its primary and all key secondary endpoints in the landmark Phase 3 SHIELD II trial for the prevention of surgical site infections.

This week we're back in MCU's Phase 1 with our final movie to review with Captain America: The First Avenger.

Join the Eat Like Ruby Podcast Community

Partner Elizabeth Avery gives us a world tour of new directions in competition law, theories of harm and merger review both here and overseas, and lessons from our role in the Paramount / Warner Bros merger. Plus news you can use on all the Phase 2s, declarations and exemptions in exceptional circumstances, scambling and other portmanteaux, and how to watch — and how definitely not to watch — The Odyssey … All this and — — — with co-hosts Moya Dodd and Matt Rubinstein. Links: Twenty Twenty Six on the BBC and the ABC How Perez Prado's Mambo No. 5 became that other one Coles's applications to the Competition Tribunal and the Federal Court L1 Dominette 01449's genome The Government's "exceptional circumstances" bill and the ACCC's class exemption The National Anti-Scam Centre's "scambling" taskforce and NSW's "betiquette" spot The Washington Post on all the ways you can watch The Odyssey Or you could read it! Meet the Gilbert + Tobin Competition, Consumer + Market Regulation team Email us at edge@gtlaw.com.au Support the show: https://www.gtlaw.com.au/See omnystudio.com/listener for privacy information.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Recent weeks have been a whirlwind of activity in the pharmaceutical and biotech sectors, showcasing significant strides in scientific breakthroughs, regulatory advancements, and strategic industry maneuvers. Replimune's Vusolimogene Oderparepvec has emerged as a beacon of hope in the fight against advanced melanoma. This gene therapy, utilizing an oncolytic virus, has recently received a positive nod from an advisory committee for its Phase 1/2 trial. When combined with PD-1 checkpoint inhibitors, it holds promise for enhancing immune responses against tumors—a critical development in cancer treatment that may redefine therapeutic strategies. This advancement follows two prior FDA rejections, underscoring the multifaceted evaluation process drugs undergo before approval and demonstrating that perseverance can eventually lead to success. Meanwhile, AstraZeneca and Daiichi Sankyo have achieved a milestone with the European Union's approval of Datopotamab Deruxtecan for treating unresectable or metastatic triple-negative breast cancer (TNBC). As an antibody-drug conjugate targeting the Trop-2 protein, it offers new hope to TNBC patients who often have limited options. This approval underscores the potential of antibody-drug conjugates in oncology, supported by promising Phase 3 trial data. Regeneron Pharmaceuticals is enjoying notable revenue growth thanks to Dupixent, a monoclonal antibody addressing autoimmune and respiratory diseases. Such financial success underscores the expanding role of biologics in tackling chronic illnesses, reflecting a broader industry trend towards biologically-based treatments. In business news, Pharmanovia's licensing deal with Impact Therapeutics for Senaparib signifies strategic expansion in oncology therapeutics. Similarly, Kaigene's agreement with Taisho Pharmaceutical highlights ongoing interest in autoimmune therapies, illustrating how companies are leveraging partnerships to broaden their therapeutic horizons. Pfizer is on the brink of expanding its label for Ritlecitinib (Litfulo), a JAK3 inhibitor that showed positive results in Phase 3 trials for nonsegmental vitiligo. By targeting autoimmune pathways, this small molecule could offer new hope to vitiligo patients seeking effective treatments. Litfulo is advancing through regulatory stages following successful trials, poised to provide an oral alternative for non-segmental vitiligo—a potential game-changer that could improve patient compliance and expand treatment options beyond Incyte's Opzelura. However, not all news is positive. Novo Nordisk faced disappointment when its Ziltivekimab failed a Phase 3 trial for atherosclerotic cardiovascular disease with chronic kidney disease. Despite this setback, Novo Nordisk remains optimistic about ongoing trials Artemis and Hermes as potential lifelines for their CKD program. Success could diversify their portfolio and introduce novel therapeutic options for CKD patients. Additionally, financial hurdles surfaced as Daiichi Sankyo saw an 11% share drop due to an accounting error, and Alnylam Pharmaceuticals' market value took a hit following a lowered revenue forecast for its TTR drug. On a global scale, the Trump administration has allocated $600 million to GAVI for childhood immunizations worldwide. This funding reversal emphasizes ongoing efforts to ensure vaccine accessibility across the globe—an essential component of public health initiatives. The dynamic nature of these developments reflects both the potential and challenges within the pharmaceutical landscape. The promising avenues presented by gene therapy, antibody-drug conjugates, and JAK inhibitors are tempered by clinical setbacks and financial volatility, underscoring the rigorous demands faced by industry stakeholders. In other industry news, AbbVie's Skyrizi continues to thrive despite increasing competition in the psoriasis market. With sales reaching $5.55 billion in Q2 2026, Skyrizi demonstrates the sustained demand for innovative biologics that enhance treatment efficacy and safety profiles. Karyopharm Therapeutics remains committed to its XPO1 inhibitor Xpovio despite setbacks in other indications like endometrial cancer. Their focus on myelofibrosis illustrates a strategic pivot towards hematologic malignancies where unmet needs persist. Oral GLP-1 receptor agonists are gaining ground as Novo Nordisk's Wegovy pill and Eli Lilly's Foundayo vie for dominance in weight management solutions. These oral formulations promise increased accessibility over traditional injectables. Regulatory arenas continue to evolve with AbbVie's Rinvoq gaining European clearance for alopecia and vitiligo. Such approvals highlight regulatory bodies' critical role in expanding market access across diverse therapeutic areas. Strategic partnerships also abound as WellSpan Health collaborates with Hippocratic AI to integrate artificial intelligence into healthcare solutions—a growing trend aimed at enhancing clinical decision-making capabilities. Meanwhile, Apnimed's $192 million IPO success indicates strong investor confidence in novel therapeutics like its sleep apnea treatment—a reflection of biopharma's financing dynamics where targeted therapies draw significant interest. Overall, these updates paint a vivid picture of an industry characterized by relentless innovation through scientific research, strategic alliances, and regulatory progress—all aimed at improving patient outcomes amidst evolving market demands. The industry's focus on breakthrough technologies continues to shape global health initiatives by offering new opportunities for patient care across various conditions. As companies navigate this dynamic environment marked by both promise and challenge—their ability to innovate scientifically while engaging strategically with regulators will be crucial to bringing novel therapies effectively into clinical practice where they can make meaningful impacts on patients' lives worldwide.Support the show

On this week's episode, Graig Suvannavejh, Tim Opler, Yaron Werber, Paul Matteis, and Brian Skorney kicked off with a review of the market, noting pressure in the XBI despite a longer-term bounce-back from trough levels, though they see biotech fundamentals as largely intact. The group also discussed the trend of reverse mergers as an alternative to traditional IPOs, along with AI's expansion and uncertain role in accelerating drug discovery. In regulatory news, the co-hosts welcomed the return of FDA advisory committee meetings, including those for Capricor and Replimune, and highlighted Anthony Fauci's recent Senate testimony on the handling of the COVID-19 pandemic. In deals, J&J struck an in vivo CAR-T partnership with Sail Biomedicines, with potential readthroughs for Legend Biotech, and Argenx is set to acquire Forte Biosciences to bolster its immunology pipeline. The group also highlighted Lilly's recent acquisition of psychedelics company AtaiBeckley, opening a broader discussion on deals in the psychedelics space. The episode concluded with company news including Alnylam shares dropping 30% following disappointing updated guidance, Novo Nordisk's Phase 3 study for its anti-IL-6 ligand antibody, and MapLight's Phase 2 schizophrenia readout. *This episode aired on July 31, 2026.

Medicus Pharma Chief Medical Officer Dr Faisal Mehmud joined Steve Darling from Proactive to discuss the company's receipt of Investigational New Drug (IND) authorization from the United Arab Emirates Department of Health – Abu Dhabi for its PRECISION-E2 Phase 2a clinical trial evaluating Teverelix® in women with moderate-to-severe symptomatic endometriosis. Mehmud said the authorization follows the Department of Health's comprehensive review of the company's chemistry, manufacturing and controls (CMC), non-clinical, clinical, and safety data, resulting in approval for the study to proceed, subject to final site-specific Institutional Review Board and ethics approvals. The PRECISION-E2 trial is a prospective, randomized, placebo-controlled Phase 2a study that will enroll approximately 84 women across multiple investigational sites in the UAE. The study will evaluate the pharmacodynamics, safety, tolerability, clinical activity, and exploratory genomic biomarkers of Teverelix®, a long-acting GnRH antagonist. Management believes the study marks an important milestone in its women's health strategy and positions Teverelix® among the first genomics-guided precision medicine programs designed to identify women with endometriosis who are most likely to benefit from targeted therapy. Endometriosis is a chronic estrogen-dependent inflammatory disease affecting approximately one in ten women of reproductive age worldwide, and Medicus believes the PRECISION-E2 study could help advance a more personalized treatment approach for patients with moderate-to-severe disease. #proactiveinvestors #nasdaq #mdcx #tsxv #mdcx #pharma #ClinicalTrials #Phase2 #Teverelix #Endometriosis #ClinicalTrials #WomensHealth #PrecisionMedicine #Biotech #DrugDevelopment #HealthcareInnovation #Phase2Trial

In this episode, we're joined by Sam Pothecary, Crystal Palace Under-9s Coach and Hampshire FA Coach Development Lead. We dive into how to support players on their football journey, the importance of individual development, and how coaches can create engaging, challenging, and player-centred environments.Whether you're coaching in grassroots or an academy setting, this podcast is designed to give you tools, ideas and inspiration to develop better players and better coaches.

Today, I want to tell you a story that sounds like it was completely made up for a movie script, but it's 100% real. Imagine an automotive mechanic in Argentina. He has zero medical training, no background in obstetrics, and no clinical degree. One night, he sees a simple party trick on YouTube: how to get a lost cork out of the inside of an empty wine bottle using nothing more than an inflated plastic bag. Most people would laugh, finish their glass of wine, and move on. But this mechanic, Jorge Odón, looked at that plastic bag and had a radical thought: Could this same basic physics principle be used to safely deliver a trapped baby during second-stage labor? Fast forward through years of engineering refinements, global partnerships, and early clinical pilots, and we get the Odón device- or OdonAssist™. It is, without a doubt, one of the most creative and innovative mechanical concepts to hit the field of operative vaginal delivery in generations. Instead of rigid metal blades applying direct compression, or high-pressure suction cups on the scalp, it uses an inflatable pneumatic cuff wrapped inside a lubricated, double-layered polyethylene sleeve. The inner layer grips the fetal vertex, while the outer layer glides smoothly against the vaginal walls, replacing high friction with plastic-on-plastic sliding action. But, and this is a big "but", as clinicians, we don't practice medicine based on good ideas or clever engineering alone. We practice based on rigorous, reproducible evidence on efficacy and safety. And that's where the narrative gets complicated. Although the device recently secured CE mark approval in Europe, it is not FDA approved in the United States. Why? Because despite nearly two decades of development, it is still facing a major shortage of large-scale Phase 3 comparative data (non-inferiority data). And the data it does have is not quite as impressive as its design would imply. Listen in for details. 1. Mottet N, et al. Safety and efficacy of the OdonAssist inflatable device for assisted vaginal birth: the BESANCON ASSIST study. American Journal of Obstetrics & Gynecology, 2023; 230, S947-S9582. Hotton EJ, Lenguerrand E, Wade J, et al. The OdonAssist inflatable device for assisted vaginal birth—the ASSIST II study (United Kingdom). Am J Obstet Gynecol. 2024;230(3S):S932-S946.e3.3. https://www.mnhi.com/odonassist (CE approval)4. ACOG PB 219; 2020.

In this episode Andrea Samadi explores Phase Three of the Brain's Operating System — how movement acts as the essential input that activates the brain, sharpens attention, boosts learning, and improves social and emotional readiness. Drawing on Dr. John Ratey's insights and related neuroscience research, she explains the chain reaction from exercise to brain activation, learning, and adaptation. The episode also emphasizes the vital role of recovery in consolidating gains so movement leads to lasting performance improvements, and invites listeners to adopt movement as a daily catalyst for clearer thinking, better learning, and greater resilience. Dr. John Ratey and The Movement Loop On this episode 404, we will: Explore where Dr. John Ratey's groundbreaking research fits within the Movement Loop. Understand how movement activates the brain and prepares us to learn. Discover why attention is the gateway to learning and performance. Connect Dr. Ratey's work with Dr. Chuck Hillman, Dr. John Medina, Kristen Holmes, and Jason Whitrock to see the bigger picture. Learn how movement becomes lasting human performance by building our capacity over time. How Movement Becomes Human Performance Welcome back to the Neuroscience Meets Social and Emotional Learning Podcast. I'm Andrea Samadi, and on this podcast, we bridge the science behind social and emotional learning, emotional intelligence, and practical neuroscience so we can create measurable improvements in well-being, achievement, productivity, and results. If you've been following along through Season 16, you'll know we've been building what I call The Brain's Operating System for Human Performance—a neuroscience-based framework that explains how movement, recovery, and adaptation work together to improve our health, learning, leadership, and performance. Over the past seven years and more than 400 episodes, I've had the privilege of interviewing neuroscientists, physicians, psychologists, educators, and high performers from around the world. As I looked across those conversations, I realized they weren't isolated ideas—they were pieces of a much larger system. I've organized that system into five interconnected phases that mirror how we grow and develop throughout life. And as we work through each of these phases, we are sharpening our saw for productivity, learning and high performance, really, with the brain and body in mind. Phase 1 is Regulation and Safety, we launched on EP 384[i] with Dr. Baland Jalal on Sleep, Safety and Curiosity. This phase is where we build the foundation by understanding the nervous system, stress, emotions, and the importance of creating internal and external safety before learning or productivity can take place. Phase 2 is Neurochemistry and Motivation, where we explore how dopamine, reward, purpose, and emotional regulation influence our choices, habits, and sustained effort. Today, we're in Phase 3: Movement, Learning, and Cognition. This is where movement becomes the catalyst that prepares the brain to pay attention, learn, adapt, and ultimately perform at a higher level. In Phase 4, we'll discover how perception and social intelligence shape the way we understand ourselves, communicate, build trust, and strengthen relationships. And finally, in Phase 5, we'll bring everything together through integration and meaning—understanding how our experiences become wisdom, resilience, purpose, and lifelong growth. Each phase builds on the one before it, because meaningful human performance isn't created in a single breakthrough—it's built one system at a time. Together, they create what I believe is the brain's operating system for human performance. If we want to improve the entire big picture of our results, we can dive deeper into these 5 phases to see what areas we could sharpen a bit. I've put the individual episodes of each phase in the show notes for a deeper dive. Today's episode is one of those foundational pieces of Phase 3. Because before we can improve performance, we first need to understand how movement changes the brain. In Episode 402[ii], we introduced The Movement Loop, built around one simple idea: Movement is the input—it's what we do. Recovery enables adaptation—it's how the brain and body grow stronger. Performance is the outcome—the results we can see, feel, and measure. Every cycle expands our capacity to learn, lead, and perform. Every movement we make sends a signal to the brain and body. That signal activates the brain— increasing blood flow, neurotransmitters, and neuroplasticity—preparing us to pay attention and learn. When movement is followed by adequate recovery, the brain and body adapt. Those adaptations become the foundation for better performance—whether that's learning more effectively, thinking more clearly, leading with greater confidence, or improving our physical health. Then, in Episode 403[iii], Dr. Chuck Hillman helped us understand why movement changes the brain. We learned that every step increases blood flow, stimulates the release of Brain-Derived Neurotrophic Factor—BDNF, often called fertilizer for the brain—and prepares the neural networks responsible for attention, learning, memory, and executive function. But understanding why movement changes the brain is only part of the story. Today's episode answers a different question: What does that actually look like in real life? How does movement change our brain? To answer that question, we're returning to one of my favorite interviews from March of 2021 with Harvard psychiatrist and bestselling author Dr. John Ratey, whose groundbreaking book Spark helped change the way millions of people think about exercise and the brain. Now, you might be wondering... "Andrea, didn't we already review Dr. Ratey's work in Episodes 375[iv] and 376[v]?" We did. But today isn't simply another review. Today we're looking at Dr. Ratey's work through an entirely new lens. When we first interviewed Dr. Ratey in 2021, I knew movement was important. But after spending the past several years interviewing experts like Dr. Chuck Hillman, Dr. John Medina, Dr. Kristen Holmes, Jason Whitrock, and hundreds of others—and measuring my own health and performance data that we'll explore throughout this season's bonus episodes—I now understand exactly where Dr. Ratey's research fits inside the Movement Loop. As I looked across all of those conversations, I realized they weren't isolated ideas. They were pieces of one much larger system. Today we're in Phase 3: Movement, Learning, and Cognition—the phase where movement becomes the catalyst for attention, learning, adaptation, and ultimately, human performance. In the coming phases, we'll discover how perception shapes our relationships, and finally how everything integrates into meaning, purpose, and lifelong growth. Today's conversation with Dr. Ratey is one of the foundational building blocks of Phase 3. Why This Matters If you've listened to this podcast for a while, you've probably heard me talk about movement as one of the few true non-negotiables in my day. Before my workday begins, I've already made time to move—not because I'm training for a race or trying to burn calories, but because I know how profoundly movement changes the way my brain performs. The research is clear. Movement prepares the brain to pay attention, learn more effectively, regulate emotions, solve problems, and perform at a higher level. I've experienced these benefits firsthand. On the days I move first, I think more clearly, I'm more productive, and I'm better equipped to handle whatever challenges the day brings. And I imagine many of you listening have experienced the same thing. Once you begin noticing how movement changes your thinking, it becomes much easier to make it a consistent part of your life. Why This Season Exists That's why my hope for Season 16 isn't simply to convince you that exercise is good for you. My goal is much bigger than that. It's to demonstrate why movement is the first step in The movement loop—and to show how every movement you make begins a chain reaction that improves learning, health, leadership, and performance. With every cycle, we don't just improve today's performance. We expand our capacity for tomorrow. As we continue exploring the Movement Loop, I hope you'll begin to see movement differently—not as another item on your to-do list, but as the input that starts an entire system of growth. Because movement isn't the goal. Movement is the beginning of everything that follows. CLIP 1: Movement Primes the Brain for Learning CLIP 1: Social Connection Reflection: Where This Fits in the Movement Loop Let's review Clip 1 with Dr. Ratey. When we listen to his clip through that lens, every sentence he shares fits into a specific step of the process. Reviewing Dr. Ratey, through the lens of The Movement Loop. Step 1: Movement — The Input Everything begins with movement. Movement is the signal we send to the brain and body that says: "It's time to wake up. It's time to adapt." Without movement, nothing else in the loop begins. As Dr. Ratey says, movement is what "turns on the thinking parts of the brain." Step 2: Brain Activation — The Brain Wakes Up This is exactly what we learned from Dr. Chuck Hillman in Episode 403[vi]. Movement immediately increases blood flow to the brain. It activates neurotransmitters. It stimulates Brain-Derived Neurotrophic Factor, or BDNF, helping create the ideal environment for learning. Dr. Hillman explained what is happening biologically. Dr. Ratey in this clip explains what we experience. You suddenly feel more alert. More awake. More ready to think. These are two perspectives describing the same process. Step 3: Attention — The Gateway to Learning This is where Dr. Ratey's words become especially powerful. He says movement helps us: stay with an idea, focus longer, evaluate information, scan our memory, and even simply stay seated long enough to think through something difficult. That isn't just better concentration. That's improved attention, and attention is the gateway to learning. Without attention, very little learning takes place. Movement prepares the brain to pay attention. At this point in the interview, he was referencing the fact that I had told him that I couldn't write podcast episodes on this topic without moving my body first. In the early days of this podcast, I found the science very difficult to understand. A couple of times I did think that this topic was over my head, and almost considered giving up. Almost, but very grateful for where the learning took me that I stuck it through. Step 4: Learning — Building New Neural Connections Once attention improves, learning becomes possible. Now the brain can: process information, make connections, strengthen memories, and solve problems more effectively. This is why Dr. Ratey says movement helps us become better learners, better thinkers, better workers, and better students. Movement isn't improving muscles first. It's improving the brain's ability to learn. Step 5: Social and Emotional Readiness One part of this interview that has become even more meaningful over time is Dr. Ratey's explanation of social connection. Exercise doesn't only improve cognition. It also changes our emotional state. We're more motivated. We regulate our emotions more effectively. We become more socially connected. Dr. Ratey explains that movement increases oxytocin—the hormone associated with bonding and trust—making us more open to connecting with others. That's important because learning has always been social. Whether we're in a classroom, at work, or with our families, our ability to connect with other people influences how well we learn, communicate, and perform. Movement prepares us socially as well as cognitively. Step 6: Recovery and Adaptation — Where Lasting Change Happens Now here's the part I didn't fully appreciate back in 2021. Everything Dr. Ratey has described prepares the brain for learning. But those immediate benefits only become lasting improvements if they're followed by recovery. Recovery is when the brain consolidates learning. It's when new neural connections are strengthened. It's when adaptation occurs. This is where Kristen Holmes' work on recovery fits perfectly into the Movement Loop. We recently reviewed our 2021 interview with Kristen Holmes on EP 390[vii] “What Gets Measured Improves: Sleep, Recovery and Strain” and it was Dr. Holmes who was (not the first person to notice I could improve my recovery scores) but was stern enough with me about how important that it was, and how I was leaving a lot off the table by not getting enough sleep/recovery to match the strain I was pushing towards each day. Movement starts the process. Recovery completes it. And together (this won't happen if one is missing) they create adaptation—the biological changes that make us stronger, healthier, and more resilient over time. The Big Takeaway When I first interviewed Dr. John Ratey in 2021, I thought he was teaching us why exercise is good for the brain. Today, after years of interviewing neuroscientists, physicians, performance experts, and educators, I see something much bigger. Dr. Ratey wasn't simply describing the benefits of exercise. He was describing the beginning of a biological process. Movement is the input. Movement activates the brain. The activated brain becomes ready to focus, learn, regulate emotions, and connect with others. Learning, when supported by recovery, leads to adaptation. Adaptation creates better performance. And every time we move through that cycle, we expand our capacity to meet tomorrow's challenges. That's the Movement Loop. It's not just a framework for understanding exercise. It's a framework for understanding how the brain changes, how we grow, and how human performance is built—one movement at a time. Review and Conclusion: The Movement Loop and Dr. Ratey To review and conclude what we've learned today. Dr. Ratey's interview wasn't simply about why exercise is good for the brain. It was about how movement begins a chain reaction that changes the way we learn, think, and perform. We discovered that: Movement is the input. Every movement sends a signal to the brain and body that it's time to change. Movement activates the brain. Blood flow increases. Neurotransmitters increase. BDNF begins preparing the brain for learning. The activated brain becomes ready. Attention improves. Executive function sharpens. Emotions become easier to regulate. We're even more prepared to connect with other people. That readiness makes learning possible. New neural pathways begin to form. The brain starts building stronger and more efficient networks. But learning doesn't end when the workout ends. Recovery allows the brain to consolidate what movement started. Recovery creates adaptation. Adaptation creates better performance. And every time we complete that cycle, we expand our capacity for whatever challenge comes next. That's the Movement Loop. This is something I've learned through years of interviewing experts, but also through measuring my own health and performance. The days I move first are always the days I think more clearly. I'm more creative with what I write as well as making connections that are important to me in my day to day life. More productive- with the entire day (family and work). More patient (with my kids and family) More present and clear. Movement doesn't solve every problem. But it prepares us to solve problems better, and increases our capacity and productivity. And that's a lesson I'll keep coming back to throughout this season. Coming Next… But there's still one important question we haven't answered. If movement activates the brain... why do some people consistently improve --while others seem to work just as hard without seeing the same results? Is it genetics? Motivation? Discipline? Or is there something happening between today's effort and tomorrow's performance? Next week, in Bonus Episode 2, we'll answer that question. We'll explore what I call The Predictable Performance System and look at years of my own recovery data to understand why recovery isn't simply the opposite of training—it's the bridge between today's habits and tomorrow's performance. Because the difference between predictable and unpredictable results... isn't luck. It's recovery. It's how we are balancing how much we push with how much we are able to rest/recover. Until next time... Keep moving. Protect your recovery. Build your capacity. And continue designing your brain's operating system for lifelong learning, health, leadership, and human performance. Thanks for joining me. I'll see you next week. RESOURCES: Clip 1 Movement and the Brain Dr. Ratey https://www.youtube.com/shorts/bbB4NzsnyQ0 Clip 1 Social Connection Dr. Ratey https://www.youtube.com/shorts/bbB4NzsnyQ0 Phase 1: Regulation & Safety The Foundation Core Question: Is the nervous system safe enough to learn? Everything begins with regulation. Before we can focus, learn, lead, or perform, the brain first asks one fundamental question: Am I safe? Throughout Phase 1, our guests showed us that regulation isn't simply about reducing stress—it's about creating the biological conditions that allow the brain to learn, adapt, and thrive. Together we explored: Baland Jalal – how sleep, curiosity, imagination, and creativity prepare the brain for learning. https://andreasamadi.podbean.com/e/hypnagogic-genius-capture-your-best-ideas-at-the-edge-of-sleep/ Dr. Bruce Perry – why regulation, rhythm, and relationships form the foundation of every healthy nervous system.  https://andreasamadi.podbean.com/e/safety-first-why-a-regulated-brain-is-the-key-to-learning/ Dr. Sui Wong – how lifestyle medicine and autonomic balance build lifelong brain resilience. https://andreasamadi.podbean.com/e/your-eyes-the-brain-s-early-warning-system/ Rohan Dixit – how heart rate variability gives us real-time feedback on our ability to regulate stress. https://andreasamadi.podbean.com/e/breathe-to-reset-how-hrv-tech-reveals-hidden-stress/ Dr. Kristen Holmes – how recovery metrics reveal our physiological readiness to perform. https://andreasamadi.podbean.com/e/kristen-holmes-from-whoopcom-on-unlocking-a-better-you-measuring-sleep-recovery-and-strain/ Dr. Antonio Zadra – how sleep and dreaming consolidate memories, regulate emotions, and generate insight. https://andreasamadi.podbean.com/e/when-brains-dream-how-sleep-integrates-emotion-insight-and-creativity/ Together these conversations taught us that sleep and stress regulation aren't optional—they're the operating system that allows every higher brain function to work. Phase 2: Motivation & Neurochemistry The Direction Core Question: What moves us into action? Once the brain feels safe, it becomes ready to pursue goals. In Phase 2, we explored the internal chemistry that transforms intention into action. Our experts helped us understand that sustainable motivation isn't about willpower—it's about aligning our beliefs, thoughts, attention, energy, and movement. Together we discovered: Bob Proctor — our beliefs determine the direction of our lives. https://andreasamadi.podbean.com/e/belief-first-the-neuroscience-of-motivation/ Dr. Carolyn Leaf — our thinking literally changes our brain chemistry. https://andreasamadi.podbean.com/e/thoughts-as-biology-how-your-mind-shapes-neurochemistry/ Dr. John Medina — attention determines what the brain encodes and remembers. https://andreasamadi.podbean.com/e/theory-of-mind-the-missing-link-between-attention-reward-and-motivation Dr. Anna Lembke- Dopamine, Motivation and Why the Brain Repeats Behavior https://andreasamadi.podbean.com/e/dopamine-nation-the-pleasure%e2%80%93pain-balance-that-drives-motivation/ Dr. Friederike Fabritius — managing our energy allows high performance to become sustainable. https://andreasamadi.podbean.com/e/fun-fear-focus-closing-the-motivation-loop/ Dr. Chuck Hillman & Paul Zientarski — movement activates the brain, preparing it to learn. https://andreasamadi.podbean.com/e/move-to-learn-how-movement-activates-the-brain-and-fuels-motivation/ By the end of Phase 2, we introduced what became The Motivation Loop, showing how beliefs influence thoughts, thoughts influence actions, actions create results, and results reinforce future beliefs. Phase 3: Movement, Learning & Human Performance The Transformation Core Question: How does movement change the brain—and how does recovery transform that change into performance? Now we're taking the next step. Phase 3 builds on everything we've learned so far. If Phase 1 created a regulated nervous system... If Phase 2 created motivation and direction... Phase 3 explains how the brain and body actually become stronger. Together we've explored this process through conversations with: Dr. Chuck Hillman & Paul Zientarski — why movement activates the brain before learning. https://andreasamadi.podbean.com/e/movement-first-how-a-20%e2%80%91minute-walk-lights-up-the-brain/ Dr. John Ratey — how exercise builds a healthier, younger brain. Dr. Kristen Holmes — why recovery determines adaptation and readiness. Dr. John Medina — how attention transforms movement into lasting learning. Jason Whitrock — how metabolism and cellular energy fuel long-term performance. WHERE WE ARE GOING NEXT Phase 4 — Connection, Emotion & Social Intelligence The Human System Core Question: How do we thrive with other people? The brain didn't evolve in isolation—it evolved through relationships. In Phase 4, we'll explore emotional intelligence, empathy, communication, trust, leadership, and psychological safety to understand how our relationships shape learning, well-being, and performance. Phase 5 — Integration & Human Performance The Complete System Core Question: How do all the systems work together? In our final phase, we'll bring everything together—regulation, motivation, movement, emotion, relationships, learning, and recovery—into one integrated framework. We'll discover how these systems work together to create measurable improvements in our well-being, achievement, leadership, productivity, and results. REFERENCES: [i] Neuroscience Meets Social and Emotional Learning Podcast EPISODE 384 https://andreasamadi.podbean.com/e/hypnagogic-genius-capture-your-best-ideas-at-the-edge-of-sleep/   [ii] Neuroscience Meets Social and Emotional Learning Podcast EPISODE 402 “Phase 3 Intro: How Movement Builds the Brain https://andreasamadi.podbean.com/e/movement-loop-how-everyday-action-rewires-your-brain-and-boosts-performance/   [iii] Neuroscience Meets Social and Emotional Learning Podcast EPISODE 403 “How movement Activates the Brain and Learning”  https://andreasamadi.podbean.com/e/movement-first-how-a-20%e2%80%91minute-walk-lights-up-the-brain/   [iv] Neuroscience Meets Social and Emotional Learning Podcast EPISODE 375 https://andreasamadi.podbean.com/e/how-exercise-primes-the-brain-insights-from-dr-john-rady/     [v] Neuroscience Meets Social and Emotional Learning Podcast EPISODE 376 https://andreasamadi.podbean.com/e/move-eat-connect-3-science-backed-keys-to-brain-health-ep-376/   [vi] Neuroscience Meets Social and Emotional Learning Podcast EPISODE 403 “How movement Activates the Brain and Learning”  https://andreasamadi.podbean.com/e/movement-first-how-a-20%e2%80%91minute-walk-lights-up-the-brain/   [vii] Neuroscience Meets Social and Emotional Learning Podcast EPISODE 390 https://andreasamadi.podbean.com/e/what-gets-measured-gets-improved-sleep-recovery-peak-performance/  

Did Marvel's Hall H panel leave you disappointed? Are you still itching to learn about installments in an ongoing high concept sci-fi universe? Well buddy we've got some great news for you, because it's time for the POD UNIVERSE IMAGINARY COMIC-CON PANEL! Just like our movies, it's not real. But it's pretty close! Join us as we answer fan-submitted questions about Phase 1 of the Pod Universe and reveal our full slate of NINE scripts for the coming season!This episode is brought to you by author Andrew Kass and his novel A Woman of Agency, available in print and ebook. You can watch a 20-minute conversation between Dylan and the author on our YouTube channel!CHAPTERS00:00:00 - Opening00:04:14 - Reflecting back on War of the Worlds00:13:08 - What we're NOT doing in Phase Two00:18:08 - Fan questions!00:42:13 - Sponsor: A Woman of Agency by Andrew Kass00:45:23 - More fan questions!01:00:35 - Slate reveal01:22:26 - Patreon, the shop, etcetera

Irrfahrt Christopher Nolans The Odyssey wirkt wie ein Film, der von Anfang an auf große Bilder und starke Stimmung setzt. Schon die Idee des Stoffes passt zu Nolans Stil: eine Reise voller Gefahr, Zweifel und Spannung, erzählt nicht klein, sondern mit dem Anspruch auf echtes Kinoerlebnis. Bildgewaltig scheint hier das passende Wort zu sein. Man erwartet keine glatte, leichte Abenteuerreise, sondern monumentale Bilder, weite Räume und Szenen, die sich förmlich ins Gedächtnis brennen. Nolan nutzt solche Stoffe oft, um aus einzelnen Momenten etwas Großes zu machen, und genau das dürfte auch hier spürbar werden. Die Reise wird nicht nur erzählt, sie wird als visuelles Erlebnis inszeniert. Düster ist der Film vermutlich ebenso. Bei Nolan steckt hinter jeder großen Geschichte meist auch ein Gefühl von Bedrohung, Verlust oder innerem Konflikt. Das passt perfekt zu einem Stoff wie The Odyssey, in dem es nicht nur um Heimkehr, sondern auch um Prüfung, Irrweg und Überleben geht. Statt reiner Abenteuerromantik entsteht so eine schwerere, ernstere Atmosphäre. Gerade darin liegt die Stärke von großem Kino: wenn Bilder, Klang und Erzählung zusammenkommen und mehr erzeugen als bloße Handlung. The Odyssey dürfte genau so ein Film sein, der nicht einfach unterhält, sondern beeindruckt. Er will nicht nebenbei laufen, sondern den Raum füllen und das Publikum komplett in seine Welt ziehen. Das ist Kino mit Anspruch, Wucht und Nachhall. Kurz gesagt: Nolan macht aus The Odyssey vermutlich kein klassisches Abenteuer, sondern ein düsteres, visuell überwältigendes Epos, das zeigt, warum Kino auf der großen Leinwand am stärksten ist. Deswegen war Matze im weltweiten größten IMAX. Noch eine Irrfahrt Wer sich wohl auch ein wenig verfahren hat ist Apple. Die Vision pro war ja ne nette Idee aber nicht wirklich das, worauf die welt gewartet hat. Das hat wohl nun auch Apple festgestellt und konzentriert sich auf das, was wohl die größeren Chancen bei der breiten Masse hat – AR Brillen. Geplant sind wohl zwei Varianten, eine mit und eine ohne Displays. Und nochmal mit dem Schiff unterwegs Assassin's Creed Black Flag Resynced wirkt wie genau das Remake, auf das viele Fans gewartet haben. Schon das Original gehört für viele zu den stärksten Teilen der Reihe, und die neue Version bringt dieses Gefühl auf der PS5 Pro noch einmal deutlich eindrucksvoller zurück. Besonders stark ist, wie gut das Spiel den Charme des Originals bewahrt und gleichzeitig moderner wirkt. Die Seefahrten, die karibische Atmosphäre und das Leben als Pirat fühlen sich immer noch frei und abenteuerlich an, aber die überarbeitete Präsentation macht alles klarer, lebendiger und insgesamt deutlich hochwertiger. Genau so sollte ein gutes Remake funktionieren: vertraut bleiben und trotzdem neu begeistern. Auf der PS5 Pro kommt diese Welt offenbar besonders gut zur Geltung. Schärfere Details, saubere Bildqualität und eine insgesamt deutlich stärkere technische Präsentation sorgen dafür, dass man noch tiefer in die tropische Spielwelt eintaucht. Das Meer wirkt bedrohlicher, die Inseln stimmungsvoller und die Kämpfe spürbar intensiver. Dadurch bekommt das Spiel eine frische Energie, ohne seinen Charakter zu verlieren. Gerade bei einem Spiel wie Black Flag ist das entscheidend, weil nicht nur die Geschichte, sondern auch das Gefühl der Freiheit trägt. Das Remake macht aus diesem Kern kein anderes Spiel, sondern ein deutlich schöneres und moderneres Erlebnis. Wer das Original mochte, bekommt hier die Chance, es in einer Form zu erleben, die dem Klassiker wirklich gerecht wird. Am Ende zeigt Assassin's Creed Black Flag Resynced vor allem eines: Ein starkes Spiel wird durch ein gutes Remake nicht ersetzt, sondern neu glänzen gelassen. Spielen wird wohl etwas teurer Zuletzt bei der Diskussion über die Steam Machine haben wir ja gehört, dass Hardware immer knapper und dadurch teurer wird. Dass sich das auch auf die alten Konsolen auswirkt dürfte so aber recht neu sein. Microsoft plant ordentliche Preiserhöhungen bei der bestehenden Konsolengeneration. Borncity berichtet von: Die Xbox Series S mit 512 GB wird dann knapp 500 Euro kosten, die 1-TB-Version schlägt mit rund 600 Euro zu Buche. Noch teurer wird es bei der High-End-Xbox Series X: Die Digital Edition ohne Laufwerk kostet künftig etwa 750 Euro, das Modell mit Disc-Laufwerk sogar rund 800 Euro. Preise sollen ab dem 1.8. gelten, wir nehmen vorher auf, deshalb können wir das nicht überprüfen. Eigentlich sollten die alten Dinger doch billiger werden. Zum Vergleich: Preise auf der Microsoft Webseite am 27.07.2026: Series X Digital, weiß, 1TB 549,99€ Series X Laufwerk Galaxy Black, 2TB 699,99€ Series S All Digital weiß 512 349,99€ Series S All Digital weiß 1TB 399,99€ Mitternacht Mitternacht von Ferris MC, Afrob feat. Jan Delay ist ein fetter Deutschrap-Track, der sofort Druck macht und mit seiner Energie hängen bleibt. Der Song hat genau diese Mischung aus Selbstbewusstsein, Härte und Flow, die einen starken Rap-Track ausmacht. Besonders stark ist, wie die drei Künstler zusammen funktionieren. Ferris MC bringt Präsenz und Kante rein, Afrob liefert diesen markanten, souveränen Rap-Style, und Jan Delay setzt mit seiner unverwechselbaren Art einen eigenen Akzent. Zusammen entsteht ein Sound, der nicht glatt wirken will, sondern direkt, eigenständig und voller Haltung ist. Der Track hat dieses typische Gefühl von Nacht, Straße und Spannung, das perfekt zum Titel passt. Mitternacht klingt nicht nach Hintergrundmusik, sondern nach einem Song, der Lautstärke braucht und Raum einnimmt. Genau das macht ihn so stark: Er wirkt entschlossen, trocken und dennoch eingängig. Auch heute hat der Song noch diesen besonderen Reiz, weil er aus einer Zeit kommt, in der Deutschrap stark über Persönlichkeit, Wortwitz und Attitüde funktioniert hat. Das macht den Track nicht nur cool, sondern auch zeitlos auf seine eigene Art. Er steht für eine Phase, in der deutscher Rap Charakter hatte und klar nach vorne ging. Am Ende bleibt Mitternacht ein Track, der zeigt, wie gut Deutschrap sein kann, wenn Haltung, Flow und Energie zusammenkommen. Ein echter Banger, der seinen Platz in der deutschen Rap-Geschichte verdient hat. Kommt das lineare glotzen zurück? Manche (inkl. Peppi) hatten gehofft, dass mit dem Streaming das goldene Zeitalter des Medienkonsums anbricht. Am Anfang war es das auch. Günstig, gute Auswahl an Inhalten, überschaubare Kosten und Anbieter. Nun gibt es viel mehr Anbieter, alle sind teurer und man muss eigentlich für jede dritte Serie wechseln wenn man nicht doppelt bezahlen will. Netflix merkt das wohl auch an immer mehr Kündigungen. Da kam nun wohl die Idee auf einen ganz alten Weg zu gehen. Offenbar denkt Netflix über das einführen von linearen Sendern nach. Was wir davon halten und wir dazu stehen im Vergleich zu Amazons senderkonzept besprechen wir in der Episode. Sony Wut! Das Ende der physischen Disc-Produktion bei Sony für PlayStation ist für viele Kunden und Gamer ein ernstes Problem. Es geht dabei nicht nur um Nostalgie, sondern um echte Fragen von Besitz, Freiheit und Verfügbarkeit. Wer Spiele heute nur noch digital kauft, ist stärker von Plattformen, Preisen und Lizenzmodellen abhängig. Eine Disc kann man weiterverkaufen, verleihen oder einfach ins Regal stellen. Eine digitale Version bleibt dagegen an ein Konto und an die Regeln des Anbieters gebunden. Genau das macht viele Spieler unruhig, weil ihnen ein Stück Kontrolle über ihre eigene Sammlung verloren geht. Für Sammler und Vielspieler ist das besonders bitter. Physische Editionen haben einen klaren Wert, der über den reinen Spielstart hinausgeht. Sie sind greifbar, unabhängig und oft auch langfristig sicherer als digitale Käufe, die theoretisch jederzeit aus dem Shop verschwinden können. Wenn Sony diesen Weg weiter konsequent verlässt, wird das Gaming für viele weniger frei und mehr von Konzernentscheidungen bestimmt. Dazu kommt ein praktischer Nachteil: Nicht jeder hat schnelles oder unbegrenztes Internet. Große Downloads, Updates und Neuinstallationen sind schon heute ein Thema. Disc-Versionen waren für viele eine einfache und verlässliche Lösung. Wenn diese Möglichkeit wegfällt, trifft das vor allem Kunden, die auf Komfort, Beständigkeit und echte Wahlfreiheit angewiesen sind. Am Ende ist das Ende der Disc-Produktion kein kleiner Fortschritt in Richtung Zukunft, sondern für viele ein Rückschritt. Es schwächt den Gebrauchtmarkt, macht Spieler abhängiger und nimmt dem Medium ein wichtiges Stück Unabhängigkeit. Genau deshalb ist dieser Schritt für Kunden und Gamer ein großes Problem.

Endlich mal wieder eine neue Folge! Mache dich bereit für ein intuitiv-astrologisches Energy Update, Real Talk zum Thema Astrologie, spirituelle Integrität und (Dis-)Empowerment plus einigen Worten über meine persönliche schmerzhafte Unterwelt-Reise der letzten Monate. Ich teile in der Episode warum es nach den intensiven Loslass-Zerfall-Prozese der letzten Monate endlich(!) Zeit für neue Hoffnung, Heilung und Visionen ist, wie wir eine Balance zwischen Schmerz & Freude, Trauer & Hoffnung, Verlust & Neugeburt finden können und warum es in der kommenden Phase garantiert NICHT darum geht „all the things“ zu machen und sich feuerpferdig zu stressen.ACHTUNG: Ich erwähne in dieser Folge (ohne ins Detail zu gehen) meinen Unfall und körperliche Schmerzen. Wenn dich das triggert, bitte sei achtsam mit dir.

Irrfahrt Christopher Nolans The Odyssey wirkt wie ein Film, der von Anfang an auf große Bilder und starke Stimmung setzt. Schon die Idee des Stoffes passt zu Nolans Stil: eine Reise voller Gefahr, Zweifel und Spannung, erzählt nicht klein, sondern mit dem Anspruch auf echtes Kinoerlebnis. Bildgewaltig scheint hier das passende Wort zu sein. Man erwartet keine glatte, leichte Abenteuerreise, sondern monumentale Bilder, weite Räume und Szenen, die sich förmlich ins Gedächtnis brennen. Nolan nutzt solche Stoffe oft, um aus einzelnen Momenten etwas Großes zu machen, und genau das dürfte auch hier spürbar werden. Die Reise wird nicht nur erzählt, sie wird als visuelles Erlebnis inszeniert. Düster ist der Film vermutlich ebenso. Bei Nolan steckt hinter jeder großen Geschichte meist auch ein Gefühl von Bedrohung, Verlust oder innerem Konflikt. Das passt perfekt zu einem Stoff wie The Odyssey, in dem es nicht nur um Heimkehr, sondern auch um Prüfung, Irrweg und Überleben geht. Statt reiner Abenteuerromantik entsteht so eine schwerere, ernstere Atmosphäre. Gerade darin liegt die Stärke von großem Kino: wenn Bilder, Klang und Erzählung zusammenkommen und mehr erzeugen als bloße Handlung. The Odyssey dürfte genau so ein Film sein, der nicht einfach unterhält, sondern beeindruckt. Er will nicht nebenbei laufen, sondern den Raum füllen und das Publikum komplett in seine Welt ziehen. Das ist Kino mit Anspruch, Wucht und Nachhall. Kurz gesagt: Nolan macht aus The Odyssey vermutlich kein klassisches Abenteuer, sondern ein düsteres, visuell überwältigendes Epos, das zeigt, warum Kino auf der großen Leinwand am stärksten ist. Deswegen war Matze im weltweiten größten IMAX. Noch eine Irrfahrt Wer sich wohl auch ein wenig verfahren hat ist Apple. Die Vision pro war ja ne nette Idee aber nicht wirklich das, worauf die welt gewartet hat. Das hat wohl nun auch Apple festgestellt und konzentriert sich auf das, was wohl die größeren Chancen bei der breiten Masse hat – AR Brillen. Geplant sind wohl zwei Varianten, eine mit und eine ohne Displays. Und nochmal mit dem Schiff unterwegs Assassin's Creed Black Flag Resynced wirkt wie genau das Remake, auf das viele Fans gewartet haben. Schon das Original gehört für viele zu den stärksten Teilen der Reihe, und die neue Version bringt dieses Gefühl auf der PS5 Pro noch einmal deutlich eindrucksvoller zurück. Besonders stark ist, wie gut das Spiel den Charme des Originals bewahrt und gleichzeitig moderner wirkt. Die Seefahrten, die karibische Atmosphäre und das Leben als Pirat fühlen sich immer noch frei und abenteuerlich an, aber die überarbeitete Präsentation macht alles klarer, lebendiger und insgesamt deutlich hochwertiger. Genau so sollte ein gutes Remake funktionieren: vertraut bleiben und trotzdem neu begeistern. Auf der PS5 Pro kommt diese Welt offenbar besonders gut zur Geltung. Schärfere Details, saubere Bildqualität und eine insgesamt deutlich stärkere technische Präsentation sorgen dafür, dass man noch tiefer in die tropische Spielwelt eintaucht. Das Meer wirkt bedrohlicher, die Inseln stimmungsvoller und die Kämpfe spürbar intensiver. Dadurch bekommt das Spiel eine frische Energie, ohne seinen Charakter zu verlieren. Gerade bei einem Spiel wie Black Flag ist das entscheidend, weil nicht nur die Geschichte, sondern auch das Gefühl der Freiheit trägt. Das Remake macht aus diesem Kern kein anderes Spiel, sondern ein deutlich schöneres und moderneres Erlebnis. Wer das Original mochte, bekommt hier die Chance, es in einer Form zu erleben, die dem Klassiker wirklich gerecht wird. Am Ende zeigt Assassin's Creed Black Flag Resynced vor allem eines: Ein starkes Spiel wird durch ein gutes Remake nicht ersetzt, sondern neu glänzen gelassen. Spielen wird wohl etwas teurer Zuletzt bei der Diskussion über die Steam Machine haben wir ja gehört, dass Hardware immer knapper und dadurch teurer wird. Dass sich das auch auf die alten Konsolen auswirkt dürfte so aber recht neu sein. Microsoft plant ordentliche Preiserhöhungen bei der bestehenden Konsolengeneration. Borncity berichtet von: Die Xbox Series S mit 512 GB wird dann knapp 500 Euro kosten, die 1-TB-Version schlägt mit rund 600 Euro zu Buche. Noch teurer wird es bei der High-End-Xbox Series X: Die Digital Edition ohne Laufwerk kostet künftig etwa 750 Euro, das Modell mit Disc-Laufwerk sogar rund 800 Euro. Preise sollen ab dem 1.8. gelten, wir nehmen vorher auf, deshalb können wir das nicht überprüfen. Eigentlich sollten die alten Dinger doch billiger werden. Zum Vergleich: Preise auf der Microsoft Webseite am 27.07.2026: Series X Digital, weiß, 1TB 549,99€ Series X Laufwerk Galaxy Black, 2TB 699,99€ Series S All Digital weiß 512 349,99€ Series S All Digital weiß 1TB 399,99€ Mitternacht Mitternacht von Ferris MC, Afrob feat. Jan Delay ist ein fetter Deutschrap-Track, der sofort Druck macht und mit seiner Energie hängen bleibt. Der Song hat genau diese Mischung aus Selbstbewusstsein, Härte und Flow, die einen starken Rap-Track ausmacht. Besonders stark ist, wie die drei Künstler zusammen funktionieren. Ferris MC bringt Präsenz und Kante rein, Afrob liefert diesen markanten, souveränen Rap-Style, und Jan Delay setzt mit seiner unverwechselbaren Art einen eigenen Akzent. Zusammen entsteht ein Sound, der nicht glatt wirken will, sondern direkt, eigenständig und voller Haltung ist. Der Track hat dieses typische Gefühl von Nacht, Straße und Spannung, das perfekt zum Titel passt. Mitternacht klingt nicht nach Hintergrundmusik, sondern nach einem Song, der Lautstärke braucht und Raum einnimmt. Genau das macht ihn so stark: Er wirkt entschlossen, trocken und dennoch eingängig. Auch heute hat der Song noch diesen besonderen Reiz, weil er aus einer Zeit kommt, in der Deutschrap stark über Persönlichkeit, Wortwitz und Attitüde funktioniert hat. Das macht den Track nicht nur cool, sondern auch zeitlos auf seine eigene Art. Er steht für eine Phase, in der deutscher Rap Charakter hatte und klar nach vorne ging. Am Ende bleibt Mitternacht ein Track, der zeigt, wie gut Deutschrap sein kann, wenn Haltung, Flow und Energie zusammenkommen. Ein echter Banger, der seinen Platz in der deutschen Rap-Geschichte verdient hat. Kommt das lineare glotzen zurück? Manche (inkl. Peppi) hatten gehofft, dass mit dem Streaming das goldene Zeitalter des Medienkonsums anbricht. Am Anfang war es das auch. Günstig, gute Auswahl an Inhalten, überschaubare Kosten und Anbieter. Nun gibt es viel mehr Anbieter, alle sind teurer und man muss eigentlich für jede dritte Serie wechseln wenn man nicht doppelt bezahlen will. Netflix merkt das wohl auch an immer mehr Kündigungen. Da kam nun wohl die Idee auf einen ganz alten Weg zu gehen. Offenbar denkt Netflix über das einführen von linearen Sendern nach. Was wir davon halten und wir dazu stehen im Vergleich zu Amazons senderkonzept besprechen wir in der Episode. Sony Wut! Das Ende der physischen Disc-Produktion bei Sony für PlayStation ist für viele Kunden und Gamer ein ernstes Problem. Es geht dabei nicht nur um Nostalgie, sondern um echte Fragen von Besitz, Freiheit und Verfügbarkeit. Wer Spiele heute nur noch digital kauft, ist stärker von Plattformen, Preisen und Lizenzmodellen abhängig. Eine Disc kann man weiterverkaufen, verleihen oder einfach ins Regal stellen. Eine digitale Version bleibt dagegen an ein Konto und an die Regeln des Anbieters gebunden. Genau das macht viele Spieler unruhig, weil ihnen ein Stück Kontrolle über ihre eigene Sammlung verloren geht. Für Sammler und Vielspieler ist das besonders bitter. Physische Editionen haben einen klaren Wert, der über den reinen Spielstart hinausgeht. Sie sind greifbar, unabhängig und oft auch langfristig sicherer als digitale Käufe, die theoretisch jederzeit aus dem Shop verschwinden können. Wenn Sony diesen Weg weiter konsequent verlässt, wird das Gaming für viele weniger frei und mehr von Konzernentscheidungen bestimmt. Dazu kommt ein praktischer Nachteil: Nicht jeder hat schnelles oder unbegrenztes Internet. Große Downloads, Updates und Neuinstallationen sind schon heute ein Thema. Disc-Versionen waren für viele eine einfache und verlässliche Lösung. Wenn diese Möglichkeit wegfällt, trifft das vor allem Kunden, die auf Komfort, Beständigkeit und echte Wahlfreiheit angewiesen sind. Am Ende ist das Ende der Disc-Produktion kein kleiner Fortschritt in Richtung Zukunft, sondern für viele ein Rückschritt. Es schwächt den Gebrauchtmarkt, macht Spieler abhängiger und nimmt dem Medium ein wichtiges Stück Unabhängigkeit. Genau deshalb ist dieser Schritt für Kunden und Gamer ein großes Problem.

Vor genau einem Jahr habe ich zum letzten Mal das Lehrerzimmer verlassen.Ich habe meine Schulsachen verschenkt.Meine Lehreridentität losgelassen.Und mich zu 100 % für meinen eigenen Weg entschieden.Zumindest dachte ich das.Denn dieses erste Jahr als Selbstständige war alles andere als leicht.Es gab Momente voller Freiheit, Leichtigkeit und tiefer Erfüllung.Aber auch Zweifel.Existenzängste.Krankheit.Und Phasen, in denen ich kurz davor war, wieder zurück in die Schule zu gehen. In dieser Folge nehme ich dich ganz ehrlich mit hinter die Kulissen.Ich erzähle dir,✨ warum ich die Schule kein einziges Mal wirklich vermisst habe✨ was mir trotzdem fehlt✨ weshalb Freiheit ohne Struktur für mich nicht funktioniert✨ wie Human Design mir geholfen hat, meinen Alltag neu zu gestalten✨ warum Sicherheit und Freiheit für mich keine Gegensätze mehr sind✨ was die schwerste Phase dieses Jahres mit unserer Ehe gemacht hat✨ und warum ich heute mehr denn je weiß, wofür ich diesen Weg gehe.Diese Folge ist für dich, wenn du gerade selbst an einem Wendepunkt stehst.Wenn du spürst, dass da noch mehr auf dich wartet.Wenn dein Herz schon längst losgehen möchte…… dein Kopf aber noch an der Sicherheit festhält.Vielleicht brauchst du heute keine Antwort.Vielleicht brauchst du einfach nur jemanden, der dir zeigt:Es darf beides da sein.Die Angst.Und der Mut.Alles Liebe,deine Hanna

Actinogen Medical Ltd managing director and CEO Dr Steven Gourlay talked with Proactive about the company's June quarter progress, including preparations for the pivotal XanaMIA Alzheimer's disease trial topline results expected in November 2026. Gourlay said the fully enrolled Phase 2b/3 trial remained on schedule, with treatment, follow-up and data-cleaning activities continuing across participating sites. He described the upcoming readout as “a potentially transformational event for the company and for the clinical science, and for patients with Alzheimer's all around the world.” An independent Data Monitoring Committee completed its third review of safety data from all 247 trial participants and recommended that the study continue without amendment. Actinogen Medical ended the quarter with $16.7 million in cash. Chief Financial Officer Will Souter said the company's current funding position was expected to support operations beyond the XanaMIA results and into mid-2027. He also highlighted potential additional funding sources, including an anticipated research and development tax rebate and the possible exercise of listed and unlisted options. Gourlay also discussed positive depression trial data published in the British Journal of Psychiatry and the company's continuing engagement with regulators, including the US Food and Drug Administration and the European Medicines Agency. Visit Proactive's YouTube channel for more company interviews and market updates. Please give the video a like, subscribe to the channel and enable notifications for future content.

Neu: Mein Programm REGULATE ist da! Wir schauen an, wie du genau diesen Konflikt endlich lösen kannst:Du willst nicht mehr trinken (aus guten Gründen und ein richtig gutes Leben ohne Alkohol führen (das sich wirklich stimmig anfühlt für dich, ohne verzichten zu müssen, ohne dich seltsam alleine zu fühlen!)... und:Gleichzeitig kannst du dir nicht vorstellen, wie du langfristig wirklich glücklich werden willst ohne oder du vertraust dir nicht, dass deine alkoholfreie Phase wirklich lange anhalten wird. Wenn du das kennst, dann ist nicht nur diese Podcastfolge für dich. Denn dort spreche ich darüber, warum gerade die Jahrgänge zwischen 1965 und 1996 mit ihrem Alkoholkonsum hadern (welche gesellschaftliche Entwicklung dahintersteckt).Sondern dann könnte auch mein neues Programm REGULATE für dich sein. Weil wir genau dort diesen inneren Konflikt lösen könnten. Alle Infos dazu findest du hier: https://www.fraubrehmer.com/regulateSo schön, dass du hier bist, deine Maria

Hello and welcome to Bill vs the MCU! Each month your hosts⁠⁠⁠⁠⁠ ⁠Pop Break Podcasting Director Alex Marcus⁠⁠⁠⁠⁠⁠ and⁠⁠⁠⁠⁠⁠ Pop Break Editor in Chief Bill Bodkin⁠⁠⁠⁠⁠⁠ are taking another step into the wider Marvel Multiverse as the MCU dives deeper into their Multiverse Saga.Bill & Alex spent all of 2022 rewatching the first four phases of the MCU, and, in the years since, they have covered the first four seasons of Agents of SHIELD, the entire Netflix Defenders Saga, Fox's X-Men,  Fantastic Four, and Daredevil films, the Blade trilogy, a few Punisher films, Ang Lee's Hulk, Marvel's Modern Animation line up of shows, and, most recently, Sony's Spider-Man and Spider-Man related films.This month, Alex & Bill bring their seven month journey through the web crawling world of Peter Parker and his amazing friends to a close with their instant reaction to Phase 6's Spider-Man: Brand New Day. To kick things off, your hosts give you some on location audio as they provide final pre-screening predictions for the film in the back of a classic New Jersey Diner. Then immediately after the screening, Alex & Bill ran back to their car in an extremely overcrowded parking lot to give you their instant reaction to all the highs and lows of this astonishing installment of Peter Parker's journey as he steps into adulthood to contend with past choices and new, unseen threats!Come back at the end of August for the start of their next season of Bill vs. The MCU entitled Agents of SHIELD Doomsday, as your favorite Marvel podcasters breakdown the world ending arcs of Agents of SHIELD's final seasons while they get ready for Avengers: Doomsday this fall. First up is Agents of SHIELD Season 5 Episodes 1-10, also known as the World Destroyed arc, available to stream on Disney Plus!

Nutritional rehabilitation receives a huge amount of attention, and rightly so. But considerably less attention is given to what comes next: learning how to build a life in which you no longer need the eating disorder.

Andabak)” The co-hosts welcome teacher and PHD student Ante Andabak to discuss the lower phase. Current events: Trump's attack on democracy heightens.

This podcast is all about founders having the capacity to grow. Nicola Anderson is a Business Growth expert and she shares her DASH framework to help founders push on from the £1-5m turnover level.Summary of the PodcastKey TakeawaysFounder Bottleneck: Business growth often stalls at £1M–£5M turnover because the founder becomes the decision-making bottleneck, losing the strategic headspace needed for further expansion.DASH Framework: Nicola Anderson's framework (Delegate, Automate, Stop, Hire) provides a structured process to create capacity to grow before hiring, which prevents costly mistakes and ensures new roles are strategic.Human-AI Integration: The most successful businesses will integrate human connection with AI efficiency. Over-reliance on AI from a single person creates significant operational risk and lacks the trust required for major deals.Strategic Exit: Founders often seek to shift from day-to-day operations to a strategic role (e.g., Chairman) to gain lifestyle freedom without full retirement, requiring a business that functions independently.The Founder Business Growth BottleneckBusinesses naturally grow around the founder, making them the central hub for all decisions.This model is sustainable to a point (e.g., £1M–£5M turnover) but eventually leads to the founder being consumed by day-to-day tasks.Consequence: Growth stalls because the founder loses the strategic headspace required for innovation, planning, and external opportunities like acquisitions.Impact: This also erodes the personal freedom and work-life balance the founder initially sought.The DASH Framework for Capacity to GrowThe DASH framework provides a structured process to create capacity to grow before hiring, preventing costly mistakes.D → Delegate: Identify tasks that can be delegated.Prerequisite: Trust in the team is essential for effective delegation.Rationale: Delegate non-core tasks to free up time for enjoyable, high-value work.A → Automate: Use technology (e.g., CRMs, AI agents) to handle repeatable tasks.S → Stop: Eliminate unnecessary activities (e.g., redundant reports, legacy spreadsheets) that add no value.H → Hire: Only hire after completing the first three steps.Rationale: This ensures new roles are strategic and prevents hiring at the wrong level (e.g., a full-time COO vs. a fractional one).Risk: Hiring too quickly creates another "wire" (decision point) for the founder if the role isn't clearly defined.Human-AI Integration & RiskThe most successful businesses will effectively integrate human talent with AI tools.Risk of AI-Only Models: Graham cited an example where a large company rejected an AI service provider after discovering it was a one-person operation.Reason: The operational risk was too high (e.g., if the person became unavailable), and the lack of human connection undermined trust.Human Connection: People buy from people they know, like, and trust, especially for significant investments. AI should support, not replace, this connection.Client Profile & EngagementTypical Clients: Founders at £1M–£5M turnover facing stalled growth, burnout, or preparing for an exit.Client Goals:Create a saleable business that doesn't depend on the founder.Shift from day-to-day operations to a strategic role (e.g., Chairman) for more lifestyle freedom.Engagement Model:Phase 1 (Intensive): A 30-day engagement for £2,500 to apply the DASH framework and create an action plan.Phase 2 (Partnership): Ongoing support for accountability and implementation, with a team of freelancers for specific tasks (e.g., CRM setup).Example: Nicola's work with David B. Horne helped him define the CEO role ("Karis") needed to transition to a Chairman position.The Next 100 Days Podcast Co-HostsGraham ArrowsmithGraham founded Finely Fettled in 2014 to provide data from The UK High Net Worth Database to marketers targeting affluent and high-net-worth customers. He's the founder of MicroYES, a Partner for MeclabsAI, creating lead generation AI Agents & Workflows and introducing the MeclabsAI Platform. Graham also provides an Answer Engine Optimisation solution to get your website in shape to be found by LLMs.Kevin ApplebyKevin specialises in finance transformation and implementing business change. He's the COO of GrowCFO, which provides both community and CPD-accredited training designed to grow the next generation of finance leaders. You can find Kevin on LinkedIn and at kevinappleby.com

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of events that underscore the dynamic nature of these industries, characterized by scientific advancements, strategic partnerships, and regulatory milestones. Johnson & Johnson has made headlines with its substantial $785 million upfront payment to Sail BioMed for an in vivo CAR-T cell therapy deal. This agreement includes an option for Johnson & Johnson to acquire Sail BioMed for $2.58 billion, underscoring the sustained interest in cell therapies, particularly for autoimmune diseases. In vivo CAR-T therapies represent a significant leap forward by modifying T cells directly within the patient's body. This method offers potential advantages over traditional ex vivo techniques by simplifying the manufacturing process and potentially reducing both costs and time to treatment. Such transactions highlight Johnson & Johnson's commitment to expanding its cell therapy portfolio, which could significantly enhance patient care by making advanced treatments more accessible. Eli Lilly and Resilience have announced a significant $750 million investment aimed at boosting the production of diabetes and obesity medications in the United States. This move comes as a response to the global rise in these conditions, necessitating increased production capacities to meet growing demand. The focus on injectable drug devices emphasizes efforts to improve drug delivery systems, ultimately enhancing patient compliance and therapeutic outcomes. Sanofi's financial outlook for 2026 is promising, driven by robust sales of Dupixent, which exceeded €5 billion in quarterly sales. Dupixent, a monoclonal antibody used for treating atopic dermatitis and other autoimmune conditions, has been a significant revenue driver for Sanofi. The success of Dupixent reflects its effectiveness and strong market adoption, highlighting the potential of monoclonal antibodies as cornerstones of modern pharmacotherapy, particularly for chronic inflammatory diseases. Regeneron and Sanofi's Dupixent continues performing strongly with $6 billion in sales during Q2 2026—marking its largest quarterly revenue since the pandemic began—illustrating robust demand across various indications within both companies' portfolios. On the regulatory front, Alfasigma's Linerixibat (Lynavoy) has received a positive opinion from the CHMP for treating cholestatic pruritus in primary biliary cholangitis following successful Phase 3 trials. As an IBAT inhibitor targeting bile acid metabolism pathways, Lynavoy introduces a novel therapeutic approach for managing symptoms associated with this autoimmune liver disease. Meanwhile, ImmunityBio's Anktiva has gained marketing authorization in the UAE for non-muscle invasive bladder cancer and metastatic non-small cell lung cancer. Anktiva, an IL-15 cytokine-based protein therapy, exemplifies the growing interest in harnessing immune system modulators for cancer treatment. Takeda's recent decision to discontinue its nanoparticle therapy (TAK-101) for celiac disease highlights the inherent challenges in developing new therapies for autoimmune disorders. The disappointing Phase 2 results suggest that achieving immune tolerance to dietary gluten remains a significant scientific hurdle. From a strategic perspective, Sanofi's CEO has emphasized stricter go/no-go decisions during Phase 3 clinical trials amid pipeline cuts and significant impairment losses. This approach could lead to more efficient resource allocation and potentially higher success rates for late-stage drug candidates. The industry is witnessing significant transformations through strategic shifts driven by executives like Sanofi's new CEO Belen Garijo. Her vision includes reversing recent challenges faced by Sanofi by capitalizing on its strengths while addressing setbacks such as discontinuing certain late-stage clinical programs like the joint venture with Regeneron on the IL-33 candidate itepekimab. This strategic pivot mirrors broader industry trends toward optimizing late-stage pipelines to enhance competitive positioning and drive future growth. Advancements in AI-powered drug discovery continue gaining momentum through collaborations like those between GSK and Relation Therapeutics, alongside Causaly and Sage. These partnerships aim to leverage AI and machine learning technologies to accelerate drug discovery processes by integrating vast amounts of scientific literature into data analytics platforms. GlaxoSmithKline's $110 million deal with an AI biotech firm further signals increased integration between artificial intelligence technologies and pharmaceutical research efforts aimed at enhancing dataset quality thereby accelerating innovation throughout drug discovery processes. Bristol Myers Squibb faces further delays regarding its Alzheimer's psychosis treatment Cobenfy—a postponement reflecting ongoing complexities related to neurological drug development which requires overcoming high scientific hurdles alongside regulatory scrutiny. Alnylam Pharmaceuticals recently experienced a 29% drop in stock value following disappointing sales of Amvuttra and a downward revision of its ATTR franchise outlook for 2026. Such fluctuations highlight volatility within biotech investments when market expectations are not met. These collective developments reveal significant trends shaping today's pharmaceutical landscape: strategic pipeline optimization efforts alongside robust investment initiatives targeting high-demand therapeutic areas—all while leveraging technological advancements like AI integration aimed at improving R&D efficiency ultimately impacting patient care worldwide through innovative therapies addressing unmet medical needs globally.Support the show

In this Company Update, I chat with Mike Spreadborough, Executive Co-Chairman, and Rohan Williams, General Manager of Exploration at Novo Resources (TSX: NVO | ASX: NVO | OTCQX: NSRPF) to discuss upcoming exploration activities at the Tibooburra Gold Project in Western Australia. Phase 2 Drilling Campaign Overview: The guys detail a 2,700-meter reverse circulation (RC) drilling program targeting high-priority prospects to build on previous high-grade intercepts. Clone Prospect Expansion Strategy: Insights into step-out plans designed to test down-plunge extensions and define structural controls of near-surface gold mineralization. Pioneer South Target Potential: An inside look at initial drill plans for a 600-meter continuous trend of outcropping gold quartz reefs returning significant rock chip assays. Earn-In Joint Venture Milestones: A breakdown of project expenditure progress, operational control transitions, and broader regional exploration initiatives. Portfolio-Wide Exploration Roadmap: Highlights from the updated corporate presentation, including near-term catalysts, regional soil programs, and active partner-led work across Australia.   Please email me with any follow up questions for Mike, Rohan, and the team at Novo Resources. My email address is Fleck@kereport.com.     Click here to visit the Novo Resources website to learn more about all the projects and exploration programs.    ------------------ For more market commentary & interview summaries, subscribe to our Substacks: The KE Report: https://kereport.substack.com/ Shad's resource market commentary: https://excelsiorprosperity.substack.com/   Investment Disclaimer: This content is for informational and educational purposes only and does not constitute investment advice, an offer, or a solicitation to buy or sell any security or investment product. Investing in equities, commodities, really everything involves risk, including the possible loss of principal. Do your own research and consult a licensed financial advisor before making any investment decisions. Guests and hosts may own shares in companies mentioned.

Get your free copy of Allison's book 'Scale or Fail' - https://pinnacleglobalnetwork.com/dna In this episode I sit down with Allison Maslan, founder and CEO of Pinnacle Global Network and Wall Street Journal bestselling author of Scale or Fail, who has personally built ten companies and helped her team mentor over 150,000 founders. We talk about why the business owner is so often the thing standing in the way of their own growth, and Allison walks me through her five phases of scaling, from the seeker all the way through what she calls the ringleader phase, the chaotic circus stage where most businesses get stuck for years. We get into how to build a team of what she calls scale multipliers instead of people who just complete tasks, why tracking your return on employee matters as much as any other business metric, and how her own burnout and health scare early in her career led her to build a completely different way of running a business. We also dig into her morning vision crafting practice and how she uses alignment to make faster, clearer decisions as a CEO. If you've ever felt like your business can't run without you, this conversation will change how you think about that. Main Topics Covered Why the founder is often the biggest bottleneck to growth The five phases of scaling a business Building a team of scale multipliers instead of task-doers Tracking return on employee (ROE) How to let go of control without losing quality Vision crafting and morning routines for clarity Using alignment to guide business decisions Why investing in mentors and masterminds speeds up growth About Allison: Allison Maslan is the founder and CEO of Pinnacle Global Network, a global business mentoring company that has helped more than 150,000 founders scale their companies from seven to nine figures. She has built ten successful companies from the ground up starting at age 19, with past clients including Ben & Jerry's, Supercuts, and Charlotte Russe. Allison is the Wall Street Journal bestselling author of Scale or Fail, endorsed by Daymond John and Barbara Corcoran, and has been featured in Forbes, Success, Fortune, and Entrepreneur Magazine. She was named one of Forbes' Top 10 Women Entrepreneurs to Watch. Website: https://pinnacleglobalnetwork.com LinkedIn: https://www.linkedin.com/in/allisonmaslan About Justin: Justin Colby is the host of The Entrepreneur DNA and The M.O.R.E Show podcasts and a best-selling author. He is a serial entrepreneur and a seasoned real estate investor with over 20 years of experience. Driven by a passion to help entrepreneurs thrive, Justin created the Entrepreneur DNA community to support business owners in building wealth, systems, and long-term freedom. Through his podcasts, books, education platforms, and hands-on mentorship, he continues to help entrepreneurs scale with clarity and confidence. Connect with Justin: Instagram: @thejustincolby YouTube: Justin Colby TikTok: @justincolbytsof  LinkedIn: Justin Colby Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

CAPITAL DOGZ guestmix: 01. AIM, Capital Dogz, Khai - Там Где Солнце 02. Broma - Joggle 03. Rockwell - Vent(Original Mix) 04. Workforce/DRS - Cheap Love 05. Koherent - Step It 06. Bredren - Evacuation 07. Vex - Forgotten(Original Mix) 08. Saikon - Guilty Pleasures(Radio Edit) 09. Monrroe/Sydney - As I Fall 10. RoyGreen & Protone - Oxy 11. Fakt - Alone In The Crowd 12. Dander - Censored The Audio - 13. RivalTechnique - Stumble 14. Data 3, Koherent- Latitude 15. Motiv - Penguin 16. Phase, Grey Code - Call In Me 17. Skeptical/SP:MC - Smelly Button 18. AIM, Capital Dogz, Khai - Раз шаг DUBSPACE LION guestmix: 01. DJ Marky, makoto, Vanessa Freeman - It's Alright, I Feel It 02. Total Science, Villem, McLeod - Outer Worlds 03. Flowrian May 04. Tokalosh - Another Level 05. Syncopix - Jonie's Theme 06. Nu:Tone - Do It Right 07. Carlito - Fiesta En La Playa 08. NC-17 / AK1200 - Summer Funk 09. Bcee - Measurement 10. SHY FX - Skanga Riddim 11. Level 2 - Bite the Bone 12. Danny Byrd, Sigma, Basslayerz - Superstylin INTELLIGENT MANNERS guestmix: 01. Intelligent Manners - Funky Joint 02. Surreal - Phases 03. Channell & Motiv & Luke Truth - Substance 04. Cnof & Harc - Paradise 05. Lenzman - Close To Me 06. Surreal - Into You 07. Primitive Instinct - Glacier Drift 08. Command Strange & Cnof - Roads 09. Chief LDN - Passion 10. Command Strange - Back To You 11. The Invisible Man - The Bell Tune (Velocity Booty) 12. Velocity - Sunny Side Up 13. Intelligent Manners - Best Place Ever 14. Unknown Artists - I Just Do GVOZD vibez: 01. High Contrast - Around Me (feat. Dawn Joseph) 02. Illarea - Between The Ages 03. Audien, Shaun Farrugia - High Hopes (Krakota Extended Remix) 04. Olly G, Gary Mictian - Back To You 05. Felix Samuel, JJONAZ, Jessee - Falling Higher (Extended Mix) 06. Tantrum Desire & Gracie Van Brunt - Lift You Up 07. Delta Heavy - Set You Free (Extended Mix) 08. SUUNE feat. Purple Velvet Curtains - Put Me On 09. del & FINAL UK - Darkest Hour 10. Paimon - Souls walk in 11. Redpill - Way of the Pack 12. Prolix - So Deep 13. SubFuze - Avalanche 14. Diode - Radial Bomb (VIP mix) 15. Burston - Heavy 16. Amott DnB - Guns 17. Dexx - Bentley 18. Khronos - Awakening 19. LowRIDERz, Smoky D - Can't Stop 20. Dub Phizix - Watchman

CAPITAL DOGZ guestmix: 01. AIM, Capital Dogz, Khai - Там Где Солнце 02. Broma - Joggle 03. Rockwell - Vent(Original Mix) 04. Workforce/DRS - Cheap Love 05. Koherent - Step It 06. Bredren - Evacuation 07. Vex - Forgotten(Original Mix) 08. Saikon - Guilty Pleasures(Radio Edit) 09. Monrroe/Sydney - As I Fall 10. RoyGreen & Protone - Oxy 11. Fakt - Alone In The Crowd 12. Dander - Censored The Audio - 13. RivalTechnique - Stumble 14. Data 3, Koherent- Latitude 15. Motiv - Penguin 16. Phase, Grey Code - Call In Me 17. Skeptical/SP:MC - Smelly Button 18. AIM, Capital Dogz, Khai - Раз шаг DUBSPACE LION guestmix: 01. DJ Marky, makoto, Vanessa Freeman - It's Alright, I Feel It 02. Total Science, Villem, McLeod - Outer Worlds 03. Flowrian May 04. Tokalosh - Another Level 05. Syncopix - Jonie's Theme 06. Nu:Tone - Do It Right 07. Carlito - Fiesta En La Playa 08. NC-17 / AK1200 - Summer Funk 09. Bcee - Measurement 10. SHY FX - Skanga Riddim 11. Level 2 - Bite the Bone 12. Danny Byrd, Sigma, Basslayerz - Superstylin INTELLIGENT MANNERS guestmix: 01. Intelligent Manners - Funky Joint 02. Surreal - Phases 03. Channell & Motiv & Luke Truth - Substance 04. Cnof & Harc - Paradise 05. Lenzman - Close To Me 06. Surreal - Into You 07. Primitive Instinct - Glacier Drift 08. Command Strange & Cnof - Roads 09. Chief LDN - Passion 10. Command Strange - Back To You 11. The Invisible Man - The Bell Tune (Velocity Booty) 12. Velocity - Sunny Side Up 13. Intelligent Manners - Best Place Ever 14. Unknown Artists - I Just Do GVOZD vibez: 01. High Contrast - Around Me (feat. Dawn Joseph) 02. Illarea - Between The Ages 03. Audien, Shaun Farrugia - High Hopes (Krakota Extended Remix) 04. Olly G, Gary Mictian - Back To You 05. Felix Samuel, JJONAZ, Jessee - Falling Higher (Extended Mix) 06. Tantrum Desire & Gracie Van Brunt - Lift You Up 07. Delta Heavy - Set You Free (Extended Mix) 08. SUUNE feat. Purple Velvet Curtains - Put Me On 09. del & FINAL UK - Darkest Hour 10. Paimon - Souls walk in 11. Redpill - Way of the Pack 12. Prolix - So Deep 13. SubFuze - Avalanche 14. Diode - Radial Bomb (VIP mix) 15. Burston - Heavy 16. Amott DnB - Guns 17. Dexx - Bentley 18. Khronos - Awakening 19. LowRIDERz, Smoky D - Can't Stop 20. Dub Phizix - Watchman

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Biogen has made a significant acquisition by purchasing Apellis Pharmaceuticals, a move expected to boost its 2026 revenue guidance with promising growth prospects. This strategic acquisition, along with strong sales from new drugs, enhances Biogen's position in the competitive market for neurological disorders. By integrating Apellis' offerings, Biogen is poised to strengthen its portfolio, particularly in areas of unmet medical need. On the regulatory front, AbbVie has achieved a milestone with its drug Rinvoq (upadacitinib), which has received dual approvals from the European Union for treating non-segmental vitiligo and severe alopecia areata. These approvals were based on successful Phase 3 data, underscoring Rinvoq's efficacy as a JAK inhibitor in tackling autoimmune conditions. This development not only highlights AbbVie's commitment to expanding its therapeutic portfolio but also positions upadacitinib as a potential mainstay treatment for dermatological autoimmune diseases. AstraZeneca Pharma India has secured approval from the Central Drugs Standard Control Organization for Enhertu (trastuzumab deruxtecan) in the neoadjuvant setting for HER2-positive early breast cancer. This approval marks a significant advancement in personalized cancer therapy, offering new hope for patients with this aggressive form of breast cancer. In terms of industry collaborations, the landscape is witnessing numerous partnerships and strategic alliances that are driving innovation forward. Skyverna Therapeutics and ElevateBio have entered a five-year clinical and commercial supply agreement for autoimmune CAR-T therapy, reflecting the growing interest in cell therapies for rare diseases. Meanwhile, Vertex Pharmaceuticals and AbCellera have joined forces to accelerate drug discovery in autoimmune T-cell engagement, supported by a $28 million upfront investment. These collaborations emphasize the importance of combining expertise and resources to advance complex therapeutic solutions. The integration of artificial intelligence in drug development continues to gain momentum. Evinova and Merck KGaA's strategic collaboration aims to leverage AI and machine learning to enhance clinical trials' efficiency, potentially ushering in a new era of precision medicine. Such partnerships highlight the transformative potential of AI in streamlining research and development processes. In funding news, Core Biomedicine has secured $21 million in Series A financing to advance its precision oncology therapeutics. Enlivex's substantial $400 million private placement aims at advancing prediction markets treasury and Allocetra immunotherapy, further accentuating the focus on personalized medicine targeting specific cancer pathways. Clinical trials have also delivered promising results. ProMIS Neurosciences reported positive interim safety and biomarker data from its Phase 1b study of PMN310 for Alzheimer's disease. This monoclonal antibody targets amyloid-beta oligomers implicated in Alzheimer's pathology, offering hope for patients with this debilitating disorder. Mergers and acquisitions remain active, exemplified by Caldera Therapeutics' reverse merger with Synlogic alongside $278 million in financing to advance its bispecific antibody for inflammatory bowel disease. This move reflects a broader trend toward consolidating resources to tackle complex autoimmune conditions. Eli Lilly's ascent to the top of Norstella's pipeline-to-patient productivity index is noteworthy, driven by successful launch strategies and rapid development cycles. This achievement underscores Eli Lilly's effective alignment of R&D efforts with market needs, particularly in areas such as GLP-1 receptor agonists that have transformed diabetes care. Teva Pharmaceuticals is demonstrating resilience through its innovative medicines portfolio amidst declining generic sales. The unexpected surge in Ajovy sales highlights Teva's pivot toward high-value branded drugs amidst competitive pressures. Novo Nordisk faces legal challenges as it navigates allegations regarding Cagrisema's Phase 3 study protocol changes. Legal scrutiny around transparency in clinical trial disclosures continues to highlight the importance of ethical practices and investor trust. Collectively, these developments illustrate a vibrant yet challenging environment where scientific advancements in immunotherapy and targeted treatments intersect with strategic business alignments focused on sustainable growth. As these trends unfold, they promise more effective treatments for complex diseases while companies adapt to an evolving market environment demanding agility and foresight. As always, stay tuned to Pharma Daily for more insights into how these transformations continue to shape the future trajectory of drug development and healthcare delivery globally.Support the show

Four heavily trafficked stretches of road in Clare could soon see their speed limits reduced from 100km/h to 80km/h under new plans. The N68 Ennis to Kilrush Road at Darragh, the R445 from the Radisson Hotel from the Limerick Border , the R352 from Ennis to Caherlohan and R458 from Ennis to Ballyline have all been included in Phase 2 of the National Speed Limit Review. Clare County Council is accepting public submissions on the proposals until August 31st. Cathaoirleach of the West Clare Municipal District, Councillor Michael Shannon says the reduction at Darragh would be a welcome start.

This fortnight, we head out on an epic sea voyage into Christopher Nolan's The Odyssey (12:59) and the dark haunted island of Widow's Bay (35:13). Plus bonus chat about the second Absolute Batman storyline and the novel The Will of the Many by James Islington.

Eine geschälte Orange und das Sydney Opera House – zwei Dinge, die auf den ersten Blick nichts miteinander zu tun haben. Doch genau darin steckt ein Prinzip, das heute genauso gilt, wenn Unternehmen ihre Daten- und AI-Landschaft aufbauen. In dieser Impuls-Folge erzählt Peter Bluhm die Geschichte des Architekten Jørn Utzon, der 1960 vor einem scheinbar unlösbaren statischen Problem stand – und zieht daraus die Lehre für den Aufbau von AI in Unternehmen. Darum geht es in dieser Episode: Was die Geschichte des Sydney Opera House mit dem Aufbau von AI in Unternehmen zu tun hat  Warum einzelne AI-Initiativen in Einkauf, Lager und Kundenservice oft auf eigenen „Dateninseln" laufen  Wieso Widersprüche zwischen AI-Modellen – anders als bei klassischen Reports – oft unbemerkt bleiben  Welche Testfragen zeigen, ob ein Unternehmen schon mitten in der „Phase der Verzweiflung" steckt  Warum eine gemeinsame, verbindliche Datengrundlage die Voraussetzung für jedes AI-Projekt ist  Der Performance Manager Podcast ist der führende deutschsprachige Podcast für Controlling, Data & AI und Performance Management. Er richtet sich an alle, die mit Daten besser entscheiden und ihr Unternehmen erfolgreicher steuern wollen. Regelmäßig begrüßt Peter Bluhm Führungskräfte, Experten und Persönlichkeiten, die in ihrem Fachgebiet zu den Besten zählen. Mit ihnen spricht er über Strategien, Inspirationen und Impulse für glasklare Entscheidungen und Erfolg im Business. Peter Bluhm ist Experte für Controlling und Data & AI sowie Buchautor. 2004 gründete er die ATVISIO Consult, eine Data- & AI-Beratung, die 2014, 2019 und 2025 mit dem Gütesiegel "Top Consultant – Die besten Berater des deutschen Mittelstandes" ausgezeichnet wurde. Neben dem "Performance Manager Podcast" ist auch Peter Bluhms Buch "Business Intelligence ganz einfach" als kostenloser Podcast verfügbar.

Interview with Steven Sirbovan, CEO, ICG Silver & GoldOur previous interview: https://www.cruxinvestor.com/posts/icg-silver-gold-cseicg-newly-listed-district-scale-play-fully-funded-for-drilling-9778Recording date: 27th July 2026ICG Silver & Gold Ltd. is a Nevada-focused precious metals explorer advancing the Tuscarora District, a roughly 10,000-acre, 100%-owned land package sitting at the intersection of the Carlin and Independence Trends in Elko County. Since listing on the CSE on 31 March 2026, the company's central task has been converting a large but fragmented historical dataset into a coherent, drill-ready district-scale thesis - and the latest update from CEO Steven Sirbovan suggests meaningful progress on that front.The headline development is data, not drilling: ICG's historical drilling database has grown from 25,000 to 40,000 metres, pulled from lab archives and physical records dating back to the 1960s. Critically, a third-party mineral resource geologist has assessed that database - combined with the company's current 3,000-metre Phase 1 RC programme - as sufficient to support a maiden inferred resource without any additional core drilling. That's a meaningful capital-efficiency win for a company with a tight, roughly 43-million-share basic capitalisation (54.5 million fully diluted).The Phase 1 programme itself, which commenced 2 July 2026 with Major Drilling International, budgeted at approximately $1.5 million, is sequencing six priority targets: Silica, Battle Mountain, and King's Vein in the Central Zone (roughly 80% of metres), followed by Grand Prize and East Pediment in the more silver-prospective East Zone, before returning to Modoc. Notably, South Navajo - the target with the deepest historical drilling and the district's best-known intercept (4.57m at 127.08 g/t gold, including 1.52m at 368.31 g/t gold, drilled by Novo Resources in 2016) - is being held back from Phase 1 entirely, with management confident in roughly 80% of the historical data there without further verification.Sirbovan has framed the programme's real objective as testing continuity rather than chasing standalone high-grade hits: understanding whether a lower-grade halo exists between known veins, and whether targets like Modoc, Silica, and Battle Mountain - previously treated as one system - are structurally connected at depth. QA/QC on both historical and current drilling is being led by VP Exploration Korbon McCall, who has been re-verifying historical assay certificates directly against lab records.Assay results are expected between August and October 2026, with a first mineral resource estimate targeted for Q1 2027 - management has cited an internal ambition of at least 500,000 gold-equivalent ounces as an initial baseline. Management, insiders, and significant shareholders hold over 25% of the tight capital structure. At an approximate C$18 million market capitalisation, ICG trades at a discount to profiled Nevada peers (C$24-160 million), several of which remain pre-resource themselves - leaving the upcoming assay and resource news flow as the key catalysts that could close that valuation gap, assuming results confirm the continuity thesis management has laid out.Learn more: https://www.cruxinvestor.com/companies/icg-silver-goldSign up for Crux Investor: https://cruxinvestor.com

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we dive into the latest news shaping these dynamic sectors, exploring strategic corporate maneuvers, groundbreaking scientific advances, and pivotal regulatory changes. GlaxoSmithKline (GSK) is embarking on a comprehensive restructuring initiative aimed at achieving $2.5 billion in annual cost savings by 2029. This ambitious initiative underscores the company's commitment to strengthening its late-stage research and development capabilities. The strategy involves optimizing mature product lines, procurement processes, and supply chain efficiencies, reflecting broader industry trends where financial prudence is balanced with innovation. As part of this transformation, GSK plans to relocate its research headquarters near AstraZeneca's facilities, though specifics on employment impacts remain under wraps. This restructuring highlights the competitive nature of the pharmaceutical landscape and GSK's intent to maintain its edge through enhanced R&D initiatives. Meanwhile, Johnson & Johnson is nearing a resolution in its extensive talc litigation by proposing a $5.5 billion settlement to resolve approximately 76,000 lawsuits. These lawsuits allege that J&J's talc-based baby powder caused ovarian cancer. This potential settlement represents a significant step toward closing a protracted chapter of legal scrutiny for J&J, offering the company a chance to mitigate ongoing legal risks and refocus on core business operations. On the regulatory front, MannKind has secured FDA approval for its fast-acting edema autoinjector, reflecting an ongoing emphasis on addressing unmet medical needs with innovative delivery mechanisms. Conversely, Baxter has issued a recall for one lot of cefazolin in dextrose injection due to contamination concerns, underscoring the continuous challenges of ensuring product safety within complex manufacturing and supply chain environments. In terms of public health initiatives, Gilead Sciences is employing a novel approach to HIV prevention through its "Up to Date" campaign featuring comedians Nicole Byer and Devon Walker. This effort aims to destigmatize HIV discussions within the Black community by leveraging humor and relatability—a testament to evolving strategies in patient engagement and education. In drug development news, Atea Pharmaceuticals is making strides with its hepatitis C treatment candidate following positive Phase 3 trial results showing equivalence with Gilead's Epclusa. This positions Atea for further clinical evaluations and potential market entry with a simplified treatment regimen. Similarly, Hansoh Pharmaceutical's collaboration with GSK has yielded another Phase 3 success for their B7-H3-directed antibody-drug conjugate in China, highlighting the growing importance of targeted therapies in oncology. Emerging biotech hubs are reshaping the industry's landscape as cities beyond traditional centers like Boston and San Francisco gain prominence. This geographical diversification reflects global trends in biotech innovation and investment. In clinical advancements, Altimmune's GLP-1/glucagon receptor-targeting drug shows promise in reducing heavy drinking among individuals with alcohol use disorder (AUD). This finding opens new therapeutic avenues for AUD by leveraging mechanisms traditionally associated with weight loss medications. Concurrently, regulatory scrutiny remains high as Replimune faces setbacks with its melanoma data package deemed "not interpretable" by the FDA—an indication of the rigorous standards required for gaining regulatory approval. The geopolitical landscape also influences industry dynamics, particularly in China where intellectual property risks are heightened under new legislative acts. Companies must navigate these complexities strategically to protect innovations while capitalizing on market opportunities. Financially, Novo Holdings-backed Claris has secured $118 million in Series B funding to advance its corneal disease drug candidate—a substantial investment underscoring growing interest in ophthalmology therapeutics. Additionally, RA Capital has launched Oak Hill Bio onto Nasdaq via a special purpose acquisition company (SPAC), focusing on rare genetic diseases—a strategy showcasing continued momentum within biotech to leverage financial tools for niche therapeutic advancements. Overall, these developments reflect an industry characterized by rapid scientific progress and evolving regulatory landscapes. Companies are under pressure to optimize operations while ensuring robust clinical data to meet regulatory standards. As these sectors strive for innovation and patient care advancements amidst competitive global markets, balancing innovation with safety and efficacy remains paramount. As always, we'll continue to track these stories closely and bring you the latest insights right here on Pharma Daily.Support the show

For years — years — the argument from the Left has been that conservatives are paranoid. That we're seeing bogeymen. That when we said the goal was to abolish your borders, dismantle your constitutional institutions, and fundamentally transform this country, we were fear-mongering. And then Megan Romer, the national co-chair of the Democratic Socialists of America, sat down with Shannon Bream on Fox News Sunday — and confirmed every single item. On camera. Without flinching. Abolish the Senate? True. Abolish ICE? Yes. Eliminate national borders? Yes. Defund the Pentagon? Yes. Phase out prisons? Yes. Replace the presidency and the Supreme Court? Yes. So let's talk about what this actually means — because this is not a fringe position anymore. This is a confessionSPONSOR: Alliance Defending FreedomAlliance Defending Freedom is representing Daniel Grand, an Orthodox Jew whose Ohio city demanded a government permit before he could host a small prayer meeting in his own home. ADF and the law firm Orrick, Herrington & Sutcliffe are now defending him at the U.S. Supreme Court, and ADF never bills its clients for their defense. For a limited time, your gift is doubled by a matching grant while matching funds last.Have your gift doubled while matching funds last. Text NICK to 83848 or give at https://www.JoinADF.com/Nick-----GET YOUR MERCH HERE: https://shop.nickjfreitas.com/BECOME A MEMBER OF THE IC: https://NickJFreitas.comInstagram: https://www.instagram.com/nickjfreitas/Facebook: https://www.facebook.com/NickFreitasVATwitter: https://twitter.com/NickJFreitasYouTube: https://www.youtube.com/@NickjfreitasTikTok: https://www.tiktok.com/@nickjfreitas3.000:00:00 – Recapping the three lies before the DSA gets honest00:03:48 – A DSA co-chair says the quiet part out loud on Fox00:06:22 – Why the DSA runs as Democrats, not a third party00:11:15 – They want to abolish the Senate, ICE, borders and the Pentagon00:16:40 – The government grocery store and the tax-subsidy shell game00:27:44 – Why the DSA won't leave the Democratic Party00:29:06 – Two messages: Mamdani's subtlety vs Romer's honesty00:32:16 – The truth will keep us free

The latest Warhammer 40k news, model releases, balance dataslate changes, and exclusive updates straight from SDCC. Latest GW Q&A: https://spikeybits.com/11th-edition-40k-qa-reveals-big-changes-for-2026/ Munitorium Field Manual Points Update: https://spikeybits.com/munitorum-field-manual-points-update-10th-edition-40k-changes-guide/ July 2026 Balance Dataslate: https://spikeybits.com/10th-edition-balance-dataslate-warhammer-40k-rules-updates-changes-guide/ Monument Hobbies has some of the best paints in the business: Get yours here https://bit.ly/MoumentHobbies Get your hobbies for less from Fabricators Forge https://bit.ly/FabricatorsForgeStore Shop BHAWK Spirits Online: https://hallingwhiskey.com/ Tequila Fortaleza 150 Years of Tradition: https://tequilafortaleza.com/ Top Hobby Supplies for miniatures: https://spikeybits.com/best-hobby-supplies-miniatures-tabletop-gaming/ Join our Discord https://discord.gg/jvVa7tT Heretic Swag https://hereticswag.com/ Table of Contents 00:00 Opening 01:50 Comic Con 21:20 News 39:37 Meat & Potatoes Become a Veteran of the Long War! http://thelongwar.net/

True change never comes easy, but it's much harder when you don't know what needs to change. Join AMBrewster as he shares the last half of necessary growth for useful family members.Truth.Love.Parent. is a podcast of Truth.Love.Family., an Evermind Ministry.Action Steps Purchase “Quit: how to stop family strife for good.” https://amzn.to/40haxLz Support our 501(c)(3) by becoming a TLP Friend! https://www.truthloveparent.com/donate.html Download the Evermind App. https://evermind.passion.io/checkout/102683 Use the promo code EVERMIND at MyPillow.com. https://www.mypillow.com/evermind  Discover the following episodes by clicking the titles or navigating to the episode in your app: A Family United in God for 50% off the normal price! https://evermind.passion.io/checkout/9d1b17c7-cd3f-4328-a362-ebc8f1cb62e5  God's Will for Your Child https://www.truthloveparent.com/gods-will-for-your-child-series.html  Biblical Conflict Resolution https://www.truthloveparent.com/biblical-conflict-resolution-440627.html  Biblical Parenting Essentials, Phase 3 | application https://www.truthloveparent.com/taking-back-the-family-blog/tlp-523-biblical-parenting-essentials-phase-3-application  Click here for Today's episode notes, resources, and transcript: https://www.truthloveparent.com/taking-back-the-family-blog/tlp-642-useful-family-relationships-part-4-the-applicationDownload the Evermind App! https://evermind.passion.io/checkout/102683Like us on Facebook: https://www.facebook.com/TruthLoveParent/Follow us on Instagram: https://www.instagram.com/truth.love.parent/Follow us on Twitter: https://twitter.com/TruthLoveParentFollow AMBrewster on Facebook: https://fb.me/TheAMBrewsterFollow AMBrewster on Instagram: https://www.instagram.com/thebrewsterhome/Follow AMBrewster on Twitter: https://twitter.com/AMBrewsterPin us on Pinterest: https://www.pinterest.com/TruthLoveParent/Subscribe to us on YouTube: https://www.youtube.com/channel/UCTHV-6sMt4p2KVSeLD-DbcwClick here for more of our social media accounts: https://www.truthloveparent.com/presskit.htmlNeed some help? Write to us at Counselor@TruthLoveParent.com.

First Milk has released a 'white paper' for regenerative dairy. The report celebrates what the co-operative dairy has achieved so far, while making a strong case for Phase 2 of their regen dairy programme - moving from measuring inputs to assessing outcomes: actual soil carbon, actual numbers of birds and insects, actual river quality... To find out more, ffinlo Costain is joined by Lee Truelove, Director of Regenerative Farming & Agriculture at First Milk, and Leona McDonald, their Director of Regenerative Partnerships.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a wealth of significant advancements and strategic moves shaping the industry landscape. AstraZeneca is making waves with its steadfast commitment to reaching an $80 billion revenue target by 2030. This ambitious goal is underpinned by strong sales in oncology and rare disease treatments, despite some setbacks with underperforming drugs like Ultomiris. The company's confidence is further reflected in its robust internal pipeline of antibody-drug conjugates (ADCs), even after discontinuing two candidates that fell short in clinical trials. This move highlights an industry-wide focus on high-potential therapeutic areas, underscoring the critical role of sustained innovation in preserving market leadership. In leadership news, Sarepta Therapeutics has appointed Michael Severino as CEO, succeeding Doug Ingram. Severino's extensive experience from AbbVie and Tessera signals a strategic shift for Sarepta, especially as it hones its focus on therapies for Duchenne Muscular Dystrophy. Leadership transitions like this can significantly impact a company's strategic direction, potentially steering it toward new therapeutic breakthroughs. On the regulatory front, Otsuka's Simtriyo has received FDA approval, marking it as a first-in-class norepinephrine, dopamine, serotonin reuptake inhibitor (NDSRI) for ADHD. This approval is a major leap forward in central nervous system therapeutics, offering a non-stimulant option that could become a blockbuster drug in this underserved market. Such advancements highlight the persistent need for innovative treatments in CNS disorders. Similarly, Outlook Therapeutics has achieved FDA approval for Lytenava, a reformulated version of Roche's Avastin for wet age-related macular degeneration (AMD). This victory, following three prior rejections, exemplifies the challenges and opportunities inherent in drug reformulation and regulatory perseverance. Corporate acquisitions continue to shape industry dynamics. Argenx's acquisition of Forte Biosciences for $2.2 billion exemplifies strategic investments aimed at expanding therapeutic portfolios. Forte's promising Phase 2-stage vitiligo drug acquisition underscores the industry's shift towards biologics in managing complex autoimmune disorders. Amgen's recent layoff of approximately 40 employees aligns with broader trends of operational optimization amidst organizational restructuring. Such workforce adjustments often reflect shifts in business strategy or responses to evolving market conditions. In clinical development news, InnoCare Pharma has announced successful Phase 3 results for its oral TYK2 inhibitor Fadeucravacitinib in treating moderate-to-severe plaque psoriasis. This achievement underscores the potential of targeted therapies in addressing autoimmune conditions by modulating specific signaling pathways. The FDA's approval of Freenome's SimpleScreen CRC blood test marks a significant advancement in non-invasive diagnostic tools for colorectal cancer screening. Such innovations could dramatically impact early cancer detection and improve patient outcomes. Meanwhile, emerging insights into CAR-T therapy have identified genetic markers linked to toxicity risks in Yescarta patients. These findings can guide future CAR-T product development towards enhanced safety profiles, offering pathways for engineering safer therapies by identifying patients at higher risk for adverse effects. Finally, the partnership between Salesforce and Veterans Affairs aims to integrate AI into healthcare workflows, illustrating the increasing role of digital transformation in enhancing healthcare delivery and operational efficiency. These developments highlight the ongoing evolution towards more personalized and efficient healthcare solutions within the pharmaceutical and biotech sectors. As companies navigate complex regulatory landscapes, pursue innovative therapies, and adapt to dynamic market demands, their efforts are poised to advance patient care standards and drive future growth within these critical industries. The implications for patient care are profound, as new treatments offer hope for conditions that have long eluded effective intervention. Stay tuned with Pharma Daily as we continue to bring you the latest updates from this rapidly evolving field.Support the show

On this episode, we discuss everything that Marvel unveiled at this year's San Diego Comic-Con, including a new GHOST RIDER movie and a new Black Panther! We also do a consensus ranking of Marvel's Phase 4 & 5. - Opening (0:30) - Marvel Comic-Con (5:24) - Other Comic-Con News (46:33) - Phase 4 & 5 Ranking (57:51) Visit insessionfilm.dashery.com to support the show with InSession Film merch! Episode sponsor: IS GOD IS - Follow us on social media for your chance to win a FREE Blu-ray of the film! Episode sponsor: koffeekult.com - Get 15% OFF with the code: ISF26 Thanks for listening and be sure to subscribe! Become an ISF VIP today to get exclusive bonus content! Follow us on Twitter! @InSessionFilm | @RealJDDuran | @BrendanJCassidy

Your dog sits when you have food. Ignores you when it matters. That's not obedience — that's negotiation. This episode covers the exact 12-step dog training progression we use at our Dorchester facility to build dogs that listen in the real world. No bribery. No guessing.

Guordan Banks visits the Mina's House Podcast to talk to Mina SayWhat about his album "The Healing Phase." They talk about healing and what that means. They also discuss his 10 year journey since releasing his debut album and "Keep You In Mind," a #1 song for him.

Following the loss of two major hospitals in south Fulton County, multiple stakeholders have worked together in recent years to bring a fully operating hospital to the area. Phase one of Grady South is already completed, with a stand-alone emergency department in Union City. But there’s more work to be done for "a medical office building offering imaging services, a surgery center, specialty clinics, pharmacy services, rehabilitation, and a full floor dedicated to pediatric care provided by Children’s Healthcare of Atlanta." Fulton County Commissioner Marvin Arrington Jr. joins “Closer Look” to discuss what it took to get the center approved. Plus, as he prepares to leave the commission, he'll reflect on his time in office including accomplishments and ongoing challenges for the county, as well as his next chapter. Also, Angela Stanley is Georgia’s new State Librarian and Vice Chancellor of Public Libraries for the University System of Georgia. We'll hear her vision re: strategic leadership for the nationally recognized Georgia Public Library Service (GPLS) and the Georgia Library Service for the Blind and Print Disabled (GLS), charting the future of library services statewide.See omnystudio.com/listener for privacy information.

Andrea Samadi shares a five-year self-experiment using a WHOOP wearable to track sleep, recovery, movement, and biological age. She reveals how daily low-intensity movement and consistent recovery—not one intense workout—produced lasting improvements in heart rate, recovery scores, and biological age. Andrea distills five lessons: movement prepares the brain, consistency beats intensity, recovery is where adaptation happens, small habits compound over time, and every step is an investment in your future brain. Practical takeaways include walking daily, adding 2–3 strength sessions per week, protecting sleep, and tracking trends instead of perfection. In this Bonus Episode you'll learn: Why recovery matters more than you think. What 1,905 recoveries taught me about human performance. Why consistency beats intensity. How movement changes the brain. How to create lasting biological adaptation. Why every walk is an investment in your future brain. EPISODE BONUS Move Today. Recover Tonight. Younger Tomorrow. Five Years. 1,905 Recoveries. One Lesson That Changed Everything. Welcome Back Welcome back to the Neuroscience Meets Social and Emotional Learning Podcast. I'm Andrea Samadi. Over the past seven years, I've had the privilege of interviewing many of the world's leading experts in neuroscience, psychology, learning, leadership, health, and human performance. Throughout Season 16, we've been connecting those conversations into a simple framework I call The Brain's Operating System for Human Performance—a practical way of understanding how the brain and body work together to help us learn better, think more clearly, live healthier, and perform at our highest potential. In Episode 402[i], we introduced The Movement Loop, built around one simple idea: Movement is the input. Adaptation is the process. Performance is the outcome. Then, in Episode 403[ii], Dr. Chuck Hillman helped us understand why movement changes the brain. Every step increases blood flow. Exercise stimulates Brain-Derived Neurotrophic Factor—BDNF—often called fertilizer for the brain. Movement strengthens the neural networks responsible for learning, memory, attention, and executive function. But after recording those episodes, I found myself asking a different question. What happens when we apply those principles consistently—not for days, weeks, or even months—but for years? Today's bonus episode is my attempt to answer that question. Not from another research study. Not from another interview. And definitely not to give you one more thing to add to your already busy schedule. Instead... I'd like to share a five-year experiment I never realized I was conducting—one that completely changed the way I think about health, movement, recovery, and human performance. Five Years Looking for the Answer When I started wearing a WHOOP device back in April of 2021, just before my fiftieth birthday, I thought I was buying a fitness tracker. I thought it would help me train harder. I thought it would reward intensity. Instead... It spent the next five years teaching me something far more valuable. How to recover. Over those five years I've tracked nearly everything I could measure. Sleep. Movement. Recovery. Resting heart rate. Heart rate variability. VO₂ Max. Biological age. Blood work. Thousands of workouts. And more than 1,905 recoveries. Nearly two thousand mornings of waking up and asking my body the same question. How well did I recover? At first, I didn't really know what I was looking for. I simply assumed the harder I trained... the healthier I'd become. The Mystery Then WHOOP introduced a new metric. WHOOP Age. The first time I looked at it, I honestly couldn't believe what I was seeing. My biological age measured 48.7 years old. I was fifty-five. More than six years younger biologically than chronologically. Of course, my first question wasn't, "That's great." My first question was... Why? What was I doing that created this result? Naturally, I assumed it was my hardest hikes. My toughest strength workouts. The mornings I pushed myself until I was completely exhausted. But that's not what the data showed. Not even close. The biggest contributor wasn't intensity. It was consistency. Daily walks. Steady hikes. Hours spent moving in Heart Rate Zones 1 through 3. The very workouts I used to think "didn't count." Ironically, even today, after finishing a workout, I still catch myself hoping to see more time in Zone 4 or Zone 5. Old beliefs don't disappear overnight. Part of me still believes harder must be better. But five years of data kept telling me a different story. A Belief I Had to Unlearn For most of my life, I believed exercise was supposed to leave me exhausted. If I wasn't completely out of breath... If I wasn't drenched in sweat... If I wasn't barely able to walk back to my car... I assumed I hadn't worked hard enough. Maybe you've felt that way too. We grew up hearing... "No pain, no gain." But neuroscience—and my own data—kept challenging that belief. The movement that felt the easiest... was quietly producing the greatest return. Daily walks. Easy hikes with friends. Walking my dogs along the canal. Consistent aerobic movement. Those weren't "easy days." Those were adaptation days. And slowly, my definition of success began to change. The Moment Everything Changed A few days ago something happened. After nearly five years... and more than 1,905 recoveries... I recorded my highest recovery ever. 98%. For a few moments I celebrated the score. Then something much more meaningful hit me. That number wasn't created overnight. It wasn't the result of one perfect night's sleep. Or one incredible workout. Or one supplement. Or one recovery tool. It represented five years of learning to work with my biology instead of against it. That's when everything finally clicked. Recovery isn't passive. Recovery is where adaptation happens. It's where muscles rebuild. It's where the brain consolidates learning. It's where the nervous system recalibrates. It's where hormones rebalance. It's where your cardiovascular system grows stronger. It's where yesterday's movement becomes tomorrow's performance. Movement starts the conversation. Recovery is where your body answers.   The Missing Piece That's when I realized something I wish someone had explained to me years ago. Movement isn't the goal. Recovery isn't even the goal. Adaptation is the goal. Movement is simply the signal that tells your biology... "Build something stronger." Recovery is when your body actually does the work. Adaptation is the result. Performance becomes the evidence. That is The Movement Loop. Move. Recover. Adapt. Perform. One connected system.   What My Data Shows When I stopped looking at individual workouts and started looking at years of trends, the story became remarkably clear. My resting heart rate dropped. My recovery improved. My biological age became younger. My weekly movement consistently averaged more than seven hours in Heart Rate Zones 1 through 3. None of those changes happened because of one extraordinary workout. They happened because of thousands of ordinary choices repeated over and over again. That's how biology changes. Quietly. Consistently. Patiently. Five Lessons Five Years and 1,905 Recoveries Taught Me Looking back over nearly five years—and more than 1,905 recoveries—I realize I wasn't simply collecting health data. I was watching my brain and body adapt in real time. Here are the five lessons I wish I had understood when I first started this journey. Lesson 1: Movement prepares the brain. One of the biggest insights from Dr. Chuck Hillman's research is that movement doesn't just strengthen our muscles—it prepares our brains to learn and perform. Every walk increases blood flow. Every hike stimulates Brain-Derived Neurotrophic Factor, or BDNF, helping the brain build and strengthen neural connections. I've noticed this in my own life. On the days I move first, I think more clearly, focus longer, solve problems more easily, and simply show up as a better version of myself. Movement isn't something I do after work anymore. It's how I prepare for my work. Lesson 2: Consistency beats intensity. For years, I believed the hardest workout was the best workout. My data taught me something completely different. The biggest improvements in my health didn't come from one exhausting hike or one intense strength session. They came from showing up every single day. Walking the canal. Taking the dogs out. Choosing another easy hike. Stopping to talk with people on the trails. It took me years to ask one person their name, after seeing them on the trails for over 10 years! Repeating those small decisions (and actions) over and over again. The body doesn't transform because we occasionally do something extraordinary. It transforms because we consistently do the ordinary. Lesson 3: Recovery is where adaptation happens. This may have been the biggest surprise of all. For years, I thought recovery meant taking a break from making progress. Now I understand that recovery is the progress. Recovery is where muscles rebuild. It's where the brain consolidates learning. It's where the nervous system recalibrates. It's where your body responds to the signal that movement created. Without recovery, movement is simply stress. With recovery, movement becomes adaptation. Lesson 4: Small daily habits create extraordinary results. When I recorded my highest recovery ever—98%—(just this week) I realized something important. That number wasn't created by one perfect night of sleep. It wasn't one workout. It wasn't one supplement. It wasn't one infrared sauna session. It represented thousands of small decisions repeated consistently over five years. Morning sunlight. Walking. Strength training. Prioritizing sleep. Breathwork. Meditation. Recovery. None of those habits seem remarkable on their own. Together, they completely changed my biology. And then I was able to create PREDICTABLE results with recovery, once I fully understood it. Lesson 5: Every step is an investment in your future brain. This may be the most important lesson of all. Most of us exercise because we want to look better or feel better today. But neuroscience tells us something even more powerful. Every walk you're taking today is helping build the brain you'll rely on years from now. Every time you move, you're strengthening the systems that support attention, memory, emotional regulation, cardiovascular health, and resilience. You may not notice those changes tomorrow. I certainly didn't. It took me nearly five years—and 1,905 recoveries—to truly appreciate what my body had been quietly building all along. That's why I no longer think of movement as exercise. I think of it as one of the greatest investments I can make in my future health, my future brain, and the quality of my life. Because every step you take today is a vote for the person you're becoming tomorrow.   Practical Application If you're wondering where to start... Start walking. Walk before work. Walk after dinner. Walk with your family. Walk with your dog. Strength train two or three times each week. It doesn't take a lot to see noticeable gains. Protect your sleep. Track trends instead of chasing perfection. Then tomorrow morning ask yourself one simple question. Not... "How hard should I train today?" Instead... How can I move today? One question. One decision. Repeated consistently. That's how change begins. Review and Conclusion As we wrap up this bonus episode, let's step back and look at what we've learned throughout this first part of Phase 3. Movement prepares the brain. Recovery builds the body. Adaptation changes our biology. Performance becomes the evidence. Five years ago, I thought movement was the goal. Today I know better. Movement is the signal. Recovery is the builder. Adaptation is the transformation (that we can see) Performance is the evidence (or what we were aiming for in the first place). After nearly 1,905 recoveries, I finally understand why recovery matters. Not because it helps us rest. Because it helps us become. Looking back, I wasn't simply collecting health data. I was watching neuroscience unfold in real time. The greatest improvements in my health didn't come from my hardest workouts. They came from thousands of ordinary decisions repeated consistently over time. We can go back to our early episodes[iii] to hear the importance of repetition. That's how human performance is built. Not through one breakthrough moment. But through daily choices that quietly reshape the brain, strengthen the body, and prepare us for whatever comes next. So wherever you're listening today... Whether you're heading out for a walk... Driving home from work... Finishing a workout... Or simply deciding how you'll move tomorrow... Remember this. Every step is a vote for your future self. Move today. Recover tonight. Adapt tomorrow. Live younger tomorrow. Until next time... Keep moving. Keep learning. Keep adapting. Because every step you take today is helping build a healthier, stronger, and more resilient version of yourself tomorrow.   REFERENCES:   [i]  Neuroscience Meets Social and Emotional Learning Podcast EPISODE 402 “Phase 3 Intro: How Movement Builds the Brain https://andreasamadi.podbean.com/e/movement-loop-how-everyday-action-rewires-your-brain-and-boosts-performance/   [ii]Neuroscience Meets Social and Emotional Learning Podcast EPISODE 403 “How movement Activates the Brain and Learning”  https://andreasamadi.podbean.com/e/movement-first-how-a-20%e2%80%91minute-walk-lights-up-the-brain/   [iii]Neuroscience Meets Social and Emotional Learning Podcast EPISODE 38 https://andreasamadi.podbean.com/e/assistant-coach-to-the-winnipeg-jets-todd-woodcroft-on-the-daily-grind-in-the-nhl/  

In this episode of our monthly series leading up to Avengers: Doomsday, Jason and Rosie are joined by producer Aaron to spotlight some the 100+ villains that have been featured in the MCU. They draft their own Phase of villains and each play a round of Keep, Recast, Kill with the remaining characters on the board. Then, they dive into some of the causes of the MCU's villain problem and debate whether Doomsday and the mutant saga beyond can finally solve it. Follow Jason: IG & Bluesky Follow Rosie: IG & Letterboxd Follow X-Ray Vision on Instagram Join the X-Ray Vision DiscordSee omnystudio.com/listener for privacy information.